Podcasts about SG

248 - David and Howard - the Bellamy Brothers In episode 248 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine!, host James Patrick Regan speaks with David and Howard, the Bellamy Brothers. In their conversation the two discusses their home in Florida and the Brahma Cattle they raise. They discuss their current tour schedule which is extreme and the logistics of their tour and they talk about 50th anniversary show at the Ryman Auditorium in Nashville on June 25th. They tell us about their connection to Ovation guitars after their gear was stolen while on tour with Loggins and Messina in the ‘70's and they also talk about the guitars they're using now on the road, Parker Fly guitars. The discuss their former bassist and lifelong friend Wally Dentz who unfortunately passed away just a couple weeks ago. They describe their early influences gospel and early country and the early English bands and they talk about playing with their dad who was also musical and they tell us about the early incarnations of their bands that eventually became the Bellamy Brothers. The tell us about the work they did early on working with and for Jim Stafford and Gallagher and David's song “Spiders and Snakes” which Jim recorded and the song “Let Your Love Flow” which jump started their career. They talk about doing tv work when tv was a very big deal and they discuss how Conway Twitty helped them break into the Nashville establishment. They discuss the members of the their band and plans for a new album to celebrate their 50th anniversary. They also talk about their other project a line of marijuana called “Old Hippy Stash” that's distributed by Trulieve. To find out more about David and Howard you can go to his website: bellamybrothers.com and they're on all the socials. Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #DavidandHowardBellamy #theBellamyBrothers #ParkerFlyGuitars #OvationGuitars #JimStafford #Gallagher #JamesPatrickRegan #ConwayTwitty #WallyDentz #theDeadlies #haveguitarwilltravelpodcast #HGWT #tourlife https://www.patreon.com/cw/HaveGuitarWillTravelPodcast Download Link

SG-1, Atlantis and Universe Prop Builder Mark Nicholson returns to Dial the Gate with more insights to building some of your favorite props from the latter half of the franchise and take your questions LIVE!

Daniel hat den Hüter des Grals geweckt: einen riesigen, feuerspeienden Wyvern. Nachdem sie den Wyvern besiegt haben, werden SG-1 und Ba'al plötzlich auf einen anderen Planeten gebeamt, wo sie Merlin in einer Stasiskammer entdecken. Deutsche TV-Premiere Mi. 29.08.2007 RTL II Original-TV-Premiere Fr. 13.04.2007 Showtime

Tales of Three Campaign OneArc 2.1: OladellEpisode 71: Evidence of ScarsIvy and Rayla get a little closer during a stop in the journey to Poletonia, while Véres finally confesses their true identity to Elara.Content Warnings: Emotional distress, traumatic past relationships, emotional conversations, romance, reference to death of a loved one, memory loss, toxic romantic relationships, ritual sacrifice, kidnappingTales of Three is an all-queer, dark fantasy dnd podcast where your three Game Masters are also your three Players!If you like what you hear please tell your friends about us & consider giving us a 5 star review! It's a quick and easy way to show your support for small creators whose content you enjoy!Follow the Cast:Arianna as Elara SpinelsparkDusty as Ivy Nightbreeze-TinkerfeyWayra as VéresFind our socials here!Want to chat with the cast, talk spoilers, play games, and make new friends? Join our Discord!If you want to help keep the podcast running and get access to bonus content check out our Patreon or buy us a coffee on Ko-fi!Special thanks to SG for theme song, Chriss for the logo, Fenn & Ely for the character art!Background music and SFX by Epidemic Sounds & Monument Studios.This week we're featuring our friends at Wyrm with a Heart. Episode 1 premieres February 28th!

247 - Philip Shouse (Solo, the Rock and Roll Residency, Accept, Ace Frehley, Gene Simmons) In episode 247 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with Philip Shouse, who has a solo EP called “Side 1” out and is currently a member of Accept he also is a part the Rock and Roll Residency and has been a part of both Gene Simmons and Ace Frehley”s solo bands. In their conversation Philip tells us about his upcoming tour of Sweden for his solo album and the band he's using and he discusses living in Nashville and the ease of traveling the world with Nashville being the hub. Philip talks about being working with the band Accept since 2017 and officially joining in 2019 and how their tour cycle works and the logistics of playing in Europe, the US and South America. Phillip tells us about his EP which was basically a 50th birthday present to himself and he tells us about the production and personel on the album. Philip describes his world of being a touring musician as opposed to the session musician scene in Nashville. Philip talks about his project “the Rock and Roll Residency” which had many special guests like Robin Zander, Alice Cooper, Billy Gibbons, Lzzy Hale to name a few. Philip takes us through his musical education and he tells us about his gear including a guitar which is very special to him. Philip describes how he ended up playing with Gene Simmons and how that led to playing with Ace Frehley. To find out more about Philip you can find him on the socials at: itsphilipshouse or his links at: linktr.ee/philipshouse.com Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #PhilipShouse #Accept #GeneSimmonsBand #AceFrehleyBand #Side1 #HagstromGuitars #GibsonGuitars #FramusGuitars #JamesPatrickRegan #theRockandRollResidency #theDeadlies #haveguitarwilltravelpodcast #HGWT #tourlife https://www.patreon.com/cw/HaveGuitarWillTravelPodcast Download Link

Years before the genre took off in film and TV, the SG-1 team became superheroes themselves! David Rich, the writer behind "Upgrades," joins us LIVE to explore the premise further!

246 - Alan Williams In episode 246 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with guitarist and music educator Alan Williams. In their conversation Alan tells us about his new solo album “Floating on the Dreamline” and the personnel and production of the album it will be released on March 6th. Alan describes growing up in North Carolina studying piano and going to New England Conservatory in Boston and deciding guitar was also suited for his talent and Alan explains his major Ethnomusicology and how that relates to his interests. Alan tells us about his early band “Knots and Crosses” and how they got signed and why they broke up. Alan talks about gear both early keyboard synths and his guitars including his guitar made by Dave Schecter and a carbon fiber guitar made by Emerald guitars (emeraldguitars.com) in Ireland and he tells us why he fears taking his guitars on the road. Alan tells us about his career at university of Massachusetts at Lowell including a run as the chair of the music department and his current role as the chair of the music business department and some of the challenges of the ever changing music industry. Alan tells us about his previous albums including one that was not initially released and has recently been remixed and released. Alan tells us about his guitar tunings that he uses both on acoustic and electric guitars. And finally Alan describes to us about his touring plans, his retirement from teaching, his wife's work, a cottage he owns on the big island of Hawaii and returning to Asheville, North Carolina. To find out more about Alan you can go to his labels website: bluegentianrecords.com or his socials @alanwilliamsevidence Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #AlanWilliams #FloatingontheDreamline #KnotsandCrosses #SchecterGuitars #EmeraldGuitars #JamesPatrickRegan #NewEnglandConservitory #theDeadlies #UMassLowell #NEC #haveguitarwilltravelpodcast #HGWT #tourlife https://www.patreon.com/cw/HaveGuitarWillTravelPodcast Download Link

Winter slips off like last season's coat, leaving only light, skin, and possibility. Spring 2026 steps in—tailored, radiant, and just a little bit irresistible.“GO Moving Towards Spring ” is a meditation on thawing — the quiet, necessary melting of winter's emotional frost. After a season of personal stillness, isolation, and reflection, January becomes a landscape of frozen habits and lingering fears ready to dissolve. Like nature preparing beneath the soil, we begin stirring things inside, shedding heaviness, releasing what no longer belongs to us, and turning instinctively toward warmth. Spring does not ask permission to arrive — it simply does — reminding us that movement is not optional, but elemental to being alive.Inspired by the rhythm of the seasons and the elegance of fashion's perpetual reinvention, this episode explores transformation as both survival and art form. Just as a runway silhouette flows forward without hesitation, we are invited to step into light with intention and glamour, carried by renewal's momentum. The world is already changing color, already softening, already moving — and so must we. We are almost there, just about to bloom. Spring approaches like a promise we are meant to walk toward, beautifully and without fear. -SG

In today's episode, Nick talks to Scryptid Games' co-directors Brigitte Winter and Nat Mesnard! We talk about their upcoming game anthology "Tales from the Cryptids." In this episode, you'll discover:How Scryptid Games builds communityWhat people can expect form this new releaseHow you can submit to get your work published in the book!Scryptid LINKS!Project link: https://scryptidgames.com/tales-from-the-cryptids Discord: https://discord.gg/jpzU3UjMVZBluesky: https://bsky.app/profile/scryptidgames.bsky.socialInstagram: https://www.instagram.com/scryptidgames/SG website: https://scryptidgames.com/Joining us is host Nick Perron. Together with his co-hosts, they bring their combined 75 years of ttrpg hobby experience to bear to answer your questions and talk about this hobby we love.Tabletopped LINKS!→ ⁠⁠⁠⁠⁠⁠⁠⁠⁠Tabletopped's website⁠⁠⁠⁠⁠⁠⁠⁠⁠→ ⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠→ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠→ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Check us out on ⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠! We have a new monthly pod as well as behind the scenes clips that you can get on a secret Spotify feed! We will also be dropping some more treats from time to time!Theme music by ⁠⁠⁠⁠⁠⁠⁠⁠⁠Mitch Poulin⁠⁠⁠⁠⁠⁠⁠⁠⁠ Support and Subscribe to the Podcast!

245 - Jeff "Skunk" Baxter In episode 245 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with guitarist Jeff “Skunk” Baxter. In their conversation Jeff tells about his role in the upcoming Rock and Roll Fantasy Camp which he does fairly often. Jeff tells us about his youth growing up in Mexico City and how he ended up playing guitar and eventually starting a surf band with Abe Laboriel. Jeff describes his early influences which are all very eclectic and Jeff talks about his move from Mexico to Connecticut and then New York City working at Jimmy's Music and the Dan Armstrong's repair shop and working on innovations with Bill Lawrence. Jeff describes the guitarists he ran into while working in New York City: Sam Brown, Eddie Deal, Danny Kortchmar and Les Paul. Jeff talks about his move to Boston to attend Boston University and working with David Schecter and studying the pedal steel. Jeff tells us about his love of muscle cars and a few of the cars he had throughout the years. Jeff discusses a few of his bands: Steely Dan and the Doobie Brothers and he talks about his session work and why he preferred to sit while playing live. Jeff talks about his love of eclectic guitars and what his collection looks like now and he talks about the work he's done for Roland, Gibson and Fender. Jeff discusses his work for the government, his hand in bringing rock music to Russia and his thoughts on new technologies and ones used during World War Two and talks a little about Nick Cook's book “the hunt for zero point”. Jeff describes being an avid reader of technical journals and guitar magazines and he talks plans for a second solo album. To find out more about Jeff you can go to his website: jeffskunkbaxter.com Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #JeffSkunkBaxter #SteelyDan #DoobieBrothers #DanArmstrong #thehuntforzeropoint #FenderGuitars #GibsonGuitars #JamesPatrickRegan #RolandMusicalInstruments #theDeadlies #haveguitarwilltravelpodcast #HGWT #tourlife https://www.patreon.com/cw/HaveGuitarWillTravelPodcast Please like, comment, and share this podcast! Download Link

Soon, employers will be expected to pay superannuation to their employees at the same time as wages. This change, known as Payday Super, becomes mandatory from 1 July 2026 and represents a once-in-a-generation reform to the superannuation system. The reform has major implications for practice owners and employers, particularly those running weekly or fortnightly payrolls, as late payments attract SG charges, interest, and loss of tax deductibility. The Bongiorno Group’s Ricky Caldow and Chantelle Turner discuss the changes and what you should be aware of between now at July. The Money Doctors is proudly brought to you by leading financial services organisation the Bongiorno Group, the preferred tax and accounting partner for the Australian Medical Association Victoria and the Victorian & Tasmanian Regional Alliance Partner of the Australian Orthopaedic Association. For more information, please call 03 9863 3111 or visit https://bongiorno.com.au/ This general advice has been prepared without taking account of your objectives, financial situation or needs. You should consider the appropriateness of this advice before acting on it. If this general advice relates to acquiring a financial product, you should obtain a Product Disclosure Statement before deciding to acquire the product. See omnystudio.com/listener for privacy information.

From Palantir and Two Sigma to building Goodfire into the poster-child for actionable mechanistic interpretability, Mark Bissell (Member of Technical Staff) and Myra Deng (Head of Product) are trying to turn “peeking inside the model” into a repeatable production workflow by shipping APIs, landing real enterprise deployments, and now scaling the bet with a recent $150M Series B funding round at a $1.25B valuation.In this episode, we go far beyond the usual “SAEs are cool” take. We talk about Goodfire's core bet: that the AI lifecycle is still fundamentally broken because the only reliable control we have is data and we post-train, RLHF, and fine-tune by “slurping supervision through a straw,” hoping the model picks up the right behaviors while quietly absorbing the wrong ones. Goodfire's answer is to build a bi-directional interface between humans and models: read what's happening inside, edit it surgically, and eventually use interpretability during training so customization isn't just brute-force guesswork.Mark and Myra walk through what that looks like when you stop treating interpretability like a lab demo and start treating it like infrastructure: lightweight probes that add near-zero latency, token-level safety filters that can run at inference time, and interpretability workflows that survive messy constraints (multilingual inputs, synthetic→real transfer, regulated domains, no access to sensitive data). We also get a live window into what “frontier-scale interp” means operationally (i.e. steering a trillion-parameter model in real time by targeting internal features) plus why the same tooling generalizes cleanly from language models to genomics, medical imaging, and “pixel-space” world models.We discuss:* Myra + Mark's path: Palantir (health systems, forward-deployed engineering) → Goodfire early team; Two Sigma → Head of Product, translating frontier interpretability research into a platform and real-world deployments* What “interpretability” actually means in practice: not just post-hoc poking, but a broader “science of deep learning” approach across the full AI lifecycle (data curation → post-training → internal representations → model design)* Why post-training is the first big wedge: “surgical edits” for unintended behaviors likereward hacking, sycophancy, noise learned during customization plus the dream of targeted unlearning and bias removal without wrecking capabilities* SAEs vs probes in the real world: why SAE feature spaces sometimes underperform classifiers trained on raw activations for downstream detection tasks (hallucination, harmful intent, PII), and what that implies about “clean concept spaces”* Rakuten in production: deploying interpretability-based token-level PII detection at inference time to prevent routing private data to downstream providers plus the gnarly constraints: no training on real customer PII, synthetic→real transfer, English + Japanese, and tokenization quirks* Why interp can be operationally cheaper than LLM-judge guardrails: probes are lightweight, low-latency, and don't require hosting a second large model in the loop* Real-time steering at frontier scale: a demo of steering Kimi K2 (~1T params) live and finding features via SAE pipelines, auto-labeling via LLMs, and toggling a “Gen-Z slang” feature across multiple layers without breaking tool use* Hallucinations as an internal signal: the case that models have latent uncertainty / “user-pleasing” circuitry you can detect and potentially mitigate more directly than black-box methods* Steering vs prompting: the emerging view that activation steering and in-context learning are more closely connected than people think, including work mapping between the two (even for jailbreak-style behaviors)* Interpretability for science: using the same tooling across domains (genomics, medical imaging, materials) to debug spurious correlations and extract new knowledge up to and including early biomarker discovery work with major partners* World models + “pixel-space” interpretability: why vision/video models make concepts easier to see, how that accelerates the feedback loop, and why robotics/world-model partners are especially interesting design partners* The north star: moving from “data in, weights out” to intentional model design where experts can impart goals and constraints directly, not just via reward signals and brute-force post-training—Goodfire AI* Website: https://goodfire.ai* LinkedIn: https://www.linkedin.com/company/goodfire-ai/* X: https://x.com/GoodfireAIMyra Deng* Website: https://myradeng.com/* LinkedIn: https://www.linkedin.com/in/myra-deng/* X: https://x.com/myra_dengMark Bissell* LinkedIn: https://www.linkedin.com/in/mark-bissell/* X: https://x.com/MarkMBissellFull Video EpisodeTimestamps00:00:00 Introduction00:00:05 Introduction to the Latent Space Podcast and Guests from Goodfire00:00:29 What is Goodfire? Mission and Focus on Interpretability00:01:01 Goodfire's Practical Approach to Interpretability00:01:37 Goodfire's Series B Fundraise Announcement00:02:04 Backgrounds of Mark and Myra from Goodfire00:02:51 Team Structure and Roles at Goodfire00:05:13 What is Interpretability? Definitions and Techniques00:05:30 Understanding Errors00:07:29 Post-training vs. Pre-training Interpretability Applications00:08:51 Using Interpretability to Remove Unwanted Behaviors00:10:09 Grokking, Double Descent, and Generalization in Models00:10:15 404 Not Found Explained00:12:06 Subliminal Learning and Hidden Biases in Models00:14:07 How Goodfire Chooses Research Directions and Projects00:15:00 Troubleshooting Errors00:16:04 Limitations of SAEs and Probes in Interpretability00:18:14 Rakuten Case Study: Production Deployment of Interpretability00:20:45 Conclusion00:21:12 Efficiency Benefits of Interpretability Techniques00:21:26 Live Demo: Real-Time Steering in a Trillion Parameter Model00:25:15 How Steering Features are Identified and Labeled00:26:51 Detecting and Mitigating Hallucinations Using Interpretability00:31:20 Equivalence of Activation Steering and Prompting00:34:06 Comparing Steering with Fine-Tuning and LoRA Techniques00:36:04 Model Design and the Future of Intentional AI Development00:38:09 Getting Started in Mechinterp: Resources, Programs, and Open Problems00:40:51 Industry Applications and the Rise of Mechinterp in Practice00:41:39 Interpretability for Code Models and Real-World Usage00:43:07 Making Steering Useful for More Than Stylistic Edits00:46:17 Applying Interpretability to Healthcare and Scientific Discovery00:49:15 Why Interpretability is Crucial in High-Stakes Domains like Healthcare00:52:03 Call for Design Partners Across Domains00:54:18 Interest in World Models and Visual Interpretability00:57:22 Sci-Fi Inspiration: Ted Chiang and Interpretability01:00:14 Interpretability, Safety, and Alignment Perspectives01:04:27 Weak-to-Strong Generalization and Future Alignment Challenges01:05:38 Final Thoughts and Hiring/Collaboration Opportunities at GoodfireTranscriptShawn Wang [00:00:05]: So welcome to the Latent Space pod. We're back in the studio with our special MechInterp co-host, Vibhu. Welcome. Mochi, Mochi's special co-host. And Mochi, the mechanistic interpretability doggo. We have with us Mark and Myra from Goodfire. Welcome. Thanks for having us on. Maybe we can sort of introduce Goodfire and then introduce you guys. How do you introduce Goodfire today?Myra Deng [00:00:29]: Yeah, it's a great question. So Goodfire, we like to say, is an AI research lab that focuses on using interpretability to understand, learn from, and design AI models. And we really believe that interpretability will unlock the new generation, next frontier of safe and powerful AI models. That's our description right now, and I'm excited to dive more into the work we're doing to make that happen.Shawn Wang [00:00:55]: Yeah. And there's always like the official description. Is there an understatement? Is there an unofficial one that sort of resonates more with a different audience?Mark Bissell [00:01:01]: Well, being an AI research lab that's focused on interpretability, there's obviously a lot of people have a lot that they think about when they think of interpretability. And I think we have a pretty broad definition of what that means and the types of places that can be applied. And in particular, applying it in production scenarios, in high stakes industries, and really taking it sort of from the research world into the real world. Which, you know. It's a new field, so that hasn't been done all that much. And we're excited about actually seeing that sort of put into practice.Shawn Wang [00:01:37]: Yeah, I would say it wasn't too long ago that Anthopic was like still putting out like toy models or superposition and that kind of stuff. And I wouldn't have pegged it to be this far along. When you and I talked at NeurIPS, you were talking a little bit about your production use cases and your customers. And then not to bury the lead, today we're also announcing the fundraise, your Series B. $150 million. $150 million at a 1.25B valuation. Congrats, Unicorn.Mark Bissell [00:02:02]: Thank you. Yeah, no, things move fast.Shawn Wang [00:02:04]: We were talking to you in December and already some big updates since then. Let's dive, I guess, into a bit of your backgrounds as well. Mark, you were at Palantir working on health stuff, which is really interesting because the Goodfire has some interesting like health use cases. I don't know how related they are in practice.Mark Bissell [00:02:22]: Yeah, not super related, but I don't know. It was helpful context to know what it's like. Just to work. Just to work with health systems and generally in that domain. Yeah.Shawn Wang [00:02:32]: And Mara, you were at Two Sigma, which actually I was also at Two Sigma back in the day. Wow, nice.Myra Deng [00:02:37]: Did we overlap at all?Shawn Wang [00:02:38]: No, this is when I was briefly a software engineer before I became a sort of developer relations person. And now you're head of product. What are your sort of respective roles, just to introduce people to like what all gets done in Goodfire?Mark Bissell [00:02:51]: Yeah, prior to Goodfire, I was at Palantir for about three years as a forward deployed engineer, now a hot term. Wasn't always that way. And as a technical lead on the health care team and at Goodfire, I'm a member of the technical staff. And honestly, that I think is about as specific as like as as I could describe myself because I've worked on a range of things. And, you know, it's it's a fun time to be at a team that's still reasonably small. I think when I joined one of the first like ten employees, now we're above 40, but still, it looks like there's always a mix of research and engineering and product and all of the above. That needs to get done. And I think everyone across the team is, you know, pretty, pretty switch hitter in the roles they do. So I think you've seen some of the stuff that I worked on related to image models, which was sort of like a research demo. More recently, I've been working on our scientific discovery team with some of our life sciences partners, but then also building out our core platform for more of like flexing some of the kind of MLE and developer skills as well.Shawn Wang [00:03:53]: Very generalist. And you also had like a very like a founding engineer type role.Myra Deng [00:03:58]: Yeah, yeah.Shawn Wang [00:03:59]: So I also started as I still am a member of technical staff, did a wide range of things from the very beginning, including like finding our office space and all of this, which is we both we both visited when you had that open house thing. It was really nice.Myra Deng [00:04:13]: Thank you. Thank you. Yeah. Plug to come visit our office.Shawn Wang [00:04:15]: It looked like it was like 200 people. It has room for 200 people. But you guys are like 10.Myra Deng [00:04:22]: For a while, it was very empty. But yeah, like like Mark, I spend. A lot of my time as as head of product, I think product is a bit of a weird role these days, but a lot of it is thinking about how do we take our frontier research and really apply it to the most important real world problems and how does that then translate into a platform that's repeatable or a product and working across, you know, the engineering and research teams to make that happen and also communicating to the world? Like, what is interpretability? What is it used for? What is it good for? Why is it so important? All of these things are part of my day-to-day as well.Shawn Wang [00:05:01]: I love like what is things because that's a very crisp like starting point for people like coming to a field. They all do a fun thing. Vibhu, why don't you want to try tackling what is interpretability and then they can correct us.Vibhu Sapra [00:05:13]: Okay, great. So I think like one, just to kick off, it's a very interesting role to be head of product, right? Because you guys, at least as a lab, you're more of an applied interp lab, right? Which is pretty different than just normal interp, like a lot of background research. But yeah. You guys actually ship an API to try these things. You have Ember, you have products around it, which not many do. Okay. What is interp? So basically you're trying to have an understanding of what's going on in model, like in the model, in the internal. So different approaches to do that. You can do probing, SAEs, transcoders, all this stuff. But basically you have an, you have a hypothesis. You have something that you want to learn about what's happening in a model internals. And then you're trying to solve that from there. You can do stuff like you can, you know, you can do activation mapping. You can try to do steering. There's a lot of stuff that you can do, but the key question is, you know, from input to output, we want to have a better understanding of what's happening and, you know, how can we, how can we adjust what's happening on the model internals? How'd I do?Mark Bissell [00:06:12]: That was really good. I think that was great. I think it's also a, it's kind of a minefield of a, if you ask 50 people who quote unquote work in interp, like what is interpretability, you'll probably get 50 different answers. And. Yeah. To some extent also like where, where good fire sits in the space. I think that we're an AI research company above all else. And interpretability is a, is a set of methods that we think are really useful and worth kind of specializing in, in order to accomplish the goals we want to accomplish. But I think we also sort of see some of the goals as even more broader as, as almost like the science of deep learning and just taking a not black box approach to kind of any part of the like AI development life cycle, whether that. That means using interp for like data curation while you're training your model or for understanding what happened during post-training or for the, you know, understanding activations and sort of internal representations, what is in there semantically. And then a lot of sort of exciting updates that were, you know, are sort of also part of the, the fundraise around bringing interpretability to training, which I don't think has been done all that much before. A lot of this stuff is sort of post-talk poking at models as opposed to. To actually using this to intentionally design them.Shawn Wang [00:07:29]: Is this post-training or pre-training or is that not a useful.Myra Deng [00:07:33]: Currently focused on post-training, but there's no reason the techniques wouldn't also work in pre-training.Shawn Wang [00:07:38]: Yeah. It seems like it would be more active, applicable post-training because basically I'm thinking like rollouts or like, you know, having different variations of a model that you can tweak with the, with your steering. Yeah.Myra Deng [00:07:50]: And I think in a lot of the news that you've seen in, in, on like Twitter or whatever, you've seen a lot of unintended. Side effects come out of post-training processes, you know, overly sycophantic models or models that exhibit strange reward hacking behavior. I think these are like extreme examples. There's also, you know, very, uh, mundane, more mundane, like enterprise use cases where, you know, they try to customize or post-train a model to do something and it learns some noise or it doesn't appropriately learn the target task. And a big question that we've always had is like, how do you use your understanding of what the model knows and what it's doing to actually guide the learning process?Shawn Wang [00:08:26]: Yeah, I mean, uh, you know, just to anchor this for people, uh, one of the biggest controversies of last year was 4.0 GlazeGate. I've never heard of GlazeGate. I didn't know that was what it was called. The other one, they called it that on the blog post and I was like, well, how did OpenAI call it? Like officially use that term. And I'm like, that's funny, but like, yeah, I guess it's the pitch that if they had worked a good fire, they wouldn't have avoided it. Like, you know what I'm saying?Myra Deng [00:08:51]: I think so. Yeah. Yeah.Mark Bissell [00:08:53]: I think that's certainly one of the use cases. I think. Yeah. Yeah. I think the reason why post-training is a place where this makes a lot of sense is a lot of what we're talking about is surgical edits. You know, you want to be able to have expert feedback, very surgically change how your model is doing, whether that is, you know, removing a certain behavior that it has. So, you know, one of the things that we've been looking at or is, is another like common area where you would want to make a somewhat surgical edit is some of the models that have say political bias. Like you look at Quen or, um, R1 and they have sort of like this CCP bias.Shawn Wang [00:09:27]: Is there a CCP vector?Mark Bissell [00:09:29]: Well, there's, there are certainly internal, yeah. Parts of the representation space where you can sort of see where that lives. Yeah. Um, and you want to kind of, you know, extract that piece out.Shawn Wang [00:09:40]: Well, I always say, you know, whenever you find a vector, a fun exercise is just like, make it very negative to see what the opposite of CCP is.Mark Bissell [00:09:47]: The super America, bald eagles flying everywhere. But yeah. So in general, like lots of post-training tasks where you'd want to be able to, to do that. Whether it's unlearning a certain behavior or, you know, some of the other kind of cases where this comes up is, are you familiar with like the, the grokking behavior? I mean, I know the machine learning term of grokking.Shawn Wang [00:10:09]: Yeah.Mark Bissell [00:10:09]: Sort of this like double descent idea of, of having a model that is able to learn a generalizing, a generalizing solution, as opposed to even if memorization of some task would suffice, you want it to learn the more general way of doing a thing. And so, you know, another. A way that you can think about having surgical access to a model's internals would be learn from this data, but learn in the right way. If there are many possible, you know, ways to, to do that. Can make interp solve the double descent problem?Shawn Wang [00:10:41]: Depends, I guess, on how you. Okay. So I, I, I viewed that double descent as a problem because then you're like, well, if the loss curves level out, then you're done, but maybe you're not done. Right. Right. But like, if you actually can interpret what is a generalizing or what you're doing. What is, what is still changing, even though the loss is not changing, then maybe you, you can actually not view it as a double descent problem. And actually you're just sort of translating the space in which you view loss and like, and then you have a smooth curve. Yeah.Mark Bissell [00:11:11]: I think that's certainly like the domain of, of problems that we're, that we're looking to get.Shawn Wang [00:11:15]: Yeah. To me, like double descent is like the biggest thing to like ML research where like, if you believe in scaling, then you don't need, you need to know where to scale. And. But if you believe in double descent, then you don't, you don't believe in anything where like anything levels off, like.Vibhu Sapra [00:11:30]: I mean, also tendentially there's like, okay, when you talk about the China vector, right. There's the subliminal learning work. It was from the anthropic fellows program where basically you can have hidden biases in a model. And as you distill down or, you know, as you train on distilled data, those biases always show up, even if like you explicitly try to not train on them. So, you know, it's just like another use case of. Okay. If we can interpret what's happening in post-training, you know, can we clear some of this? Can we even determine what's there? Because yeah, it's just like some worrying research that's out there that shows, you know, we really don't know what's going on.Mark Bissell [00:12:06]: That is. Yeah. I think that's the biggest sentiment that we're sort of hoping to tackle. Nobody knows what's going on. Right. Like subliminal learning is just an insane concept when you think about it. Right. Train a model on not even the logits, literally the output text of a bunch of random numbers. And now your model loves owls. And you see behaviors like that, that are just, they defy, they defy intuition. And, and there are mathematical explanations that you can get into, but. I mean.Shawn Wang [00:12:34]: It feels so early days. Objectively, there are a sequence of numbers that are more owl-like than others. There, there should be.Mark Bissell [00:12:40]: According to, according to certain models. Right. It's interesting. I think it only applies to models that were initialized from the same starting Z. Usually, yes.Shawn Wang [00:12:49]: But I mean, I think that's a, that's a cheat code because there's not enough compute. But like if you believe in like platonic representation, like probably it will transfer across different models as well. Oh, you think so?Mark Bissell [00:13:00]: I think of it more as a statistical artifact of models initialized from the same seed sort of. There's something that is like path dependent from that seed that might cause certain overlaps in the latent space and then sort of doing this distillation. Yeah. Like it pushes it towards having certain other tendencies.Vibhu Sapra [00:13:24]: Got it. I think there's like a bunch of these open-ended questions, right? Like you can't train in new stuff during the RL phase, right? RL only reorganizes weights and you can only do stuff that's somewhat there in your base model. You're not learning new stuff. You're just reordering chains and stuff. But okay. My broader question is when you guys work at an interp lab, how do you decide what to work on and what's kind of the thought process? Right. Because we can ramble for hours. Okay. I want to know this. I want to know that. But like, how do you concretely like, you know, what's the workflow? Okay. There's like approaches towards solving a problem, right? I can try prompting. I can look at chain of thought. I can train probes, SAEs. But how do you determine, you know, like, okay, is this going anywhere? Like, do we have set stuff? Just, you know, if you can help me with all that. Yeah.Myra Deng [00:14:07]: It's a really good question. I feel like we've always at the very beginning of the company thought about like, let's go and try to learn what isn't working in machine learning today. Whether that's talking to customers or talking to researchers at other labs, trying to understand both where the frontier is going and where things are really not falling apart today. And then developing a perspective on how we can push the frontier using interpretability methods. And so, you know, even our chief scientist, Tom, spends a lot of time talking to customers and trying to understand what real world problems are and then taking that back and trying to apply the current state of the art to those problems and then seeing where they fall down basically. And then using those failures or those shortcomings to understand what hills to climb when it comes to interpretability research. So like on the fundamental side, for instance, when we have done some work applying SAEs and probes, we've encountered, you know, some shortcomings in SAEs that we found a little bit surprising. And so have gone back to the drawing board and done work on that. And then, you know, we've done some work on better foundational interpreter models. And a lot of our team's research is focused on what is the next evolution beyond SAEs, for instance. And then when it comes to like control and design of models, you know, we tried steering with our first API and realized that it still fell short of black box techniques like prompting or fine tuning. And so went back to the drawing board and we're like, how do we make that not the case and how do we improve it beyond that? And one of our researchers, Ekdeep, who just joined is actually Ekdeep and Atticus are like steering experts and have spent a lot of time trying to figure out like, what is the research that enables us to actually do this in a much more powerful, robust way? So yeah, the answer is like, look at real world problems, try to translate that into a research agenda and then like hill climb on both of those at the same time.Shawn Wang [00:16:04]: Yeah. Mark has the steering CLI demo queued up, which we're going to go into in a sec. But I always want to double click on when you drop hints, like we found some problems with SAEs. Okay. What are they? You know, and then we can go into the demo. Yeah.Myra Deng [00:16:19]: I mean, I'm curious if you have more thoughts here as well, because you've done it in the healthcare domain. But I think like, for instance, when we do things like trying to detect behaviors within models that are harmful or like behaviors that a user might not want to have in their model. So hallucinations, for instance, harmful intent, PII, all of these things. We first tried using SAE probes for a lot of these tasks. So taking the feature activation space from SAEs and then training classifiers on top of that, and then seeing how well we can detect the properties that we might want to detect in model behavior. And we've seen in many cases that probes just trained on raw activations seem to perform better than SAE probes, which is a bit surprising if you think that SAEs are actually also capturing the concepts that you would want to capture cleanly and more surgically. And so that is an interesting observation. I don't think that is like, I'm not down on SAEs at all. I think there are many, many things they're useful for, but we have definitely run into cases where I think the concept space described by SAEs is not as clean and accurate as we would expect it to be for actual like real world downstream performance metrics.Mark Bissell [00:17:34]: Fair enough. Yeah. It's the blessing and the curse of unsupervised methods where you get to peek into the AI's mind. But sometimes you wish that you saw other things when you walked inside there. Although in the PII instance, I think weren't an SAE based approach actually did prove to be the most generalizable?Myra Deng [00:17:53]: It did work well in the case that we published with Rakuten. And I think a lot of the reasons it worked well was because we had a noisier data set. And so actually the blessing of unsupervised learning is that we actually got to get more meaningful, generalizable signal from SAEs when the data was noisy. But in other cases where we've had like good data sets, it hasn't been the case.Shawn Wang [00:18:14]: And just because you named Rakuten and I don't know if we'll get it another chance, like what is the overall, like what is Rakuten's usage or production usage? Yeah.Myra Deng [00:18:25]: So they are using us to essentially guardrail and inference time monitor their language model usage and their agent usage to detect things like PII so that they don't route private user information.Myra Deng [00:18:41]: And so that's, you know, going through all of their user queries every day. And that's something that we deployed with them a few months ago. And now we are actually exploring very early partnerships, not just with Rakuten, but with other people around how we can help with potentially training and customization use cases as well. Yeah.Shawn Wang [00:19:03]: And for those who don't know, like it's Rakuten is like, I think number one or number two e-commerce store in Japan. Yes. Yeah.Mark Bissell [00:19:10]: And I think that use case actually highlights a lot of like what it looks like to deploy things in practice that you don't always think about when you're doing sort of research tasks. So when you think about some of the stuff that came up there that's more complex than your idealized version of a problem, they were encountering things like synthetic to real transfer of methods. So they couldn't train probes, classifiers, things like that on actual customer data of PII. So what they had to do is use synthetic data sets. And then hope that that transfer is out of domain to real data sets. And so we can evaluate performance on the real data sets, but not train on customer PII. So that right off the bat is like a big challenge. You have multilingual requirements. So this needed to work for both English and Japanese text. Japanese text has all sorts of quirks, including tokenization behaviors that caused lots of bugs that caused us to be pulling our hair out. And then also a lot of tasks you'll see. You might make simplifying assumptions if you're sort of treating it as like the easiest version of the problem to just sort of get like general results where maybe you say you're classifying a sentence to say, does this contain PII? But the need that Rakuten had was token level classification so that you could precisely scrub out the PII. So as we learned more about the problem, you're sort of speaking about what that looks like in practice. Yeah. A lot of assumptions end up breaking. And that was just one instance where you. A problem that seems simple right off the bat ends up being more complex as you keep diving into it.Vibhu Sapra [00:20:41]: Excellent. One of the things that's also interesting with Interp is a lot of these methods are very efficient, right? So where you're just looking at a model's internals itself compared to a separate like guardrail, LLM as a judge, a separate model. One, you have to host it. Two, there's like a whole latency. So if you use like a big model, you have a second call. Some of the work around like self detection of hallucination, it's also deployed for efficiency, right? So if you have someone like Rakuten doing it in production live, you know, that's just another thing people should consider.Mark Bissell [00:21:12]: Yeah. And something like a probe is super lightweight. Yeah. It's no extra latency really. Excellent.Shawn Wang [00:21:17]: You have the steering demos lined up. So we were just kind of see what you got. I don't, I don't actually know if this is like the latest, latest or like alpha thing.Mark Bissell [00:21:26]: No, this is a pretty hacky demo from from a presentation that someone else on the team recently gave. So this will give a sense for, for technology. So you can see the steering and action. Honestly, I think the biggest thing that this highlights is that as we've been growing as a company and taking on kind of more and more ambitious versions of interpretability related problems, a lot of that comes to scaling up in various different forms. And so here you're going to see steering on a 1 trillion parameter model. This is Kimi K2. And so it's sort of fun that in addition to the research challenges, there are engineering challenges that we're now tackling. Cause for any of this to be sort of useful in production, you need to be thinking about what it looks like when you're using these methods on frontier models as opposed to sort of like toy kind of model organisms. So yeah, this was thrown together hastily, pretty fragile behind the scenes, but I think it's quite a fun demo. So screen sharing is on. So I've got two terminal sessions pulled up here. On the left is a forked version that we have of the Kimi CLI that we've got running to point at our custom hosted Kimi model. And then on the right is a set up that will allow us to steer on certain concepts. So I should be able to chat with Kimi over here. Tell it hello. This is running locally. So the CLI is running locally, but the Kimi server is running back to the office. Well, hopefully should be, um, that's too much to run on that Mac. Yeah. I think it's, uh, it takes a full, like each 100 node. I think it's like, you can. You can run it on eight GPUs, eight 100. So, so yeah, Kimi's running. We can ask it a prompt. It's got a forked version of our, uh, of the SG line code base that we've been working on. So I'm going to tell it, Hey, this SG line code base is slow. I think there's a bug. Can you try to figure it out? There's a big code base, so it'll, it'll spend some time doing this. And then on the right here, I'm going to initialize in real time. Some steering. Let's see here.Mark Bissell [00:23:33]: searching for any. Bugs. Feature ID 43205.Shawn Wang [00:23:38]: Yeah.Mark Bissell [00:23:38]: 20, 30, 40. So let me, uh, this is basically a feature that we found that inside Kimi seems to cause it to speak in Gen Z slang. And so on the left, it's still sort of thinking normally it might take, I don't know, 15 seconds for this to kick in, but then we're going to start hopefully seeing him do this code base is massive for real. So we're going to start. We're going to start seeing Kimi transition as the steering kicks in from normal Kimi to Gen Z Kimi and both in its chain of thought and its actual outputs.Mark Bissell [00:24:19]: And interestingly, you can see, you know, it's still able to call tools, uh, and stuff. It's um, it's purely sort of it's it's demeanor. And there are other features that we found for interesting things like concision. So that's more of a practical one. You can make it more concise. Um, the types of programs, uh, programming languages that uses, but yeah, as we're seeing it come in. Pretty good. Outputs.Shawn Wang [00:24:43]: Scheduler code is actually wild.Vibhu Sapra [00:24:46]: Yo, this code is actually insane, bro.Vibhu Sapra [00:24:53]: What's the process of training in SAE on this, or, you know, how do you label features? I know you guys put out a pretty cool blog post about, um, finding this like autonomous interp. Um, something. Something about how agents for interp is different than like coding agents. I don't know while this is spewing up, but how, how do we find feature 43, two Oh five. Yeah.Mark Bissell [00:25:15]: So in this case, um, we, our platform that we've been building out for a long time now supports all the sort of classic out of the box interp techniques that you might want to have like SAE training, probing things of that kind, I'd say the techniques for like vanilla SAEs are pretty well established now where. You take your model that you're interpreting, run a whole bunch of data through it, gather activations, and then yeah, pretty straightforward pipeline to train an SAE. There are a lot of different varieties. There's top KSAEs, batch top KSAEs, um, normal ReLU SAEs. And then once you have your sparse features to your point, assigning labels to them to actually understand that this is a gen Z feature, that's actually where a lot of the kind of magic happens. Yeah. And the most basic standard technique is look at all of your d input data set examples that cause this feature to fire most highly. And then you can usually pick out a pattern. So for this feature, If I've run a diverse enough data set through my model feature 43, two Oh five. Probably tends to fire on all the tokens that sounds like gen Z slang. You know, that's the, that's the time of year to be like, Oh, I'm in this, I'm in this Um, and, um, so, you know, you could have a human go through all 43,000 concepts andVibhu Sapra [00:26:34]: And I've got to ask the basic question, you know, can we get examples where it hallucinates, pass it through, see what feature activates for hallucinations? Can I just, you know, turn hallucination down?Myra Deng [00:26:51]: Oh, wow. You really predicted a project we're already working on right now, which is detecting hallucinations using interpretability techniques. And this is interesting because hallucinations is something that's very hard to detect. And it's like a kind of a hairy problem and something that black box methods really struggle with. Whereas like Gen Z, you could always train a simple classifier to detect that hallucinations is harder. But we've seen that models internally have some... Awareness of like uncertainty or some sort of like user pleasing behavior that leads to hallucinatory behavior. And so, yeah, we have a project that's trying to detect that accurately. And then also working on mitigating the hallucinatory behavior in the model itself as well.Shawn Wang [00:27:39]: Yeah, I would say most people are still at the level of like, oh, I would just turn temperature to zero and that turns off hallucination. And I'm like, well, that's a fundamental misunderstanding of how this works. Yeah.Mark Bissell [00:27:51]: Although, so part of what I like about that question is you, there are SAE based approaches that might like help you get at that. But oftentimes the beauty of SAEs and like we said, the curse is that they're unsupervised. So when you have a behavior that you deliberately would like to remove, and that's more of like a supervised task, often it is better to use something like probes and specifically target the thing that you're interested in reducing as opposed to sort of like hoping that when you fragment the latent space, one of the vectors that pops out.Vibhu Sapra [00:28:20]: And as much as we're training an autoencoder to be sparse, we're not like for sure certain that, you know, we will get something that just correlates to hallucination. You'll probably split that up into 20 other things and who knows what they'll be.Mark Bissell [00:28:36]: Of course. Right. Yeah. So there's no sort of problems with like feature splitting and feature absorption. And then there's the off target effects, right? Ideally, you would want to be very precise where if you reduce the hallucination feature, suddenly maybe your model can't write. Creatively anymore. And maybe you don't like that, but you want to still stop it from hallucinating facts and figures.Shawn Wang [00:28:55]: Good. So Vibhu has a paper to recommend there that we'll put in the show notes. But yeah, I mean, I guess just because your demo is done, any any other things that you want to highlight or any other interesting features you want to show?Mark Bissell [00:29:07]: I don't think so. Yeah. Like I said, this is a pretty small snippet. I think the main sort of point here that I think is exciting is that there's not a whole lot of inter being applied to models quite at this scale. You know, Anthropic certainly has some some. Research and yeah, other other teams as well. But it's it's nice to see these techniques, you know, being put into practice. I think not that long ago, the idea of real time steering of a trillion parameter model would have sounded.Shawn Wang [00:29:33]: Yeah. The fact that it's real time, like you started the thing and then you edited the steering vector.Vibhu Sapra [00:29:38]: I think it's it's an interesting one TBD of what the actual like production use case would be on that, like the real time editing. It's like that's the fun part of the demo, right? You can kind of see how this could be served behind an API, right? Like, yes, you're you only have so many knobs and you can just tweak it a bit more. And I don't know how it plays in. Like people haven't done that much with like, how does this work with or without prompting? Right. How does this work with fine tuning? Like, there's a whole hype of continual learning, right? So there's just so much to see. Like, is this another parameter? Like, is it like parameter? We just kind of leave it as a default. We don't use it. So I don't know. Maybe someone here wants to put out a guide on like how to use this with prompting when to do what?Mark Bissell [00:30:18]: Oh, well, I have a paper recommendation. I think you would love from Act Deep on our team, who is an amazing researcher, just can't say enough amazing things about Act Deep. But he actually has a paper that as well as some others from the team and elsewhere that go into the essentially equivalence of activation steering and in context learning and how those are from a he thinks of everything in a cognitive neuroscience Bayesian framework, but basically how you can precisely show how. Prompting in context, learning and steering exhibit similar behaviors and even like get quantitative about the like magnitude of steering you would need to do to induce a certain amount of behavior similar to certain prompting, even for things like jailbreaks and stuff. It's a really cool paper. Are you saying steering is less powerful than prompting? More like you can almost write a formula that tells you how to convert between the two of them.Myra Deng [00:31:20]: And so like formally equivalent actually in the in the limit. Right.Mark Bissell [00:31:24]: So like one case study of this is for jailbreaks there. I don't know. Have you seen the stuff where you can do like many shot jailbreaking? You like flood the context with examples of the behavior. And the topic put out that paper.Shawn Wang [00:31:38]: A lot of people were like, yeah, we've been doing this, guys.Mark Bissell [00:31:40]: Like, yeah, what's in this in context learning and activation steering equivalence paper is you can like predict the number. Number of examples that you will need to put in there in order to jailbreak the model. That's cool. By doing steering experiments and using this sort of like equivalence mapping. That's cool. That's really cool. It's very neat. Yeah.Shawn Wang [00:32:02]: I was going to say, like, you know, I can like back rationalize that this makes sense because, you know, what context is, is basically just, you know, it updates the KV cache kind of and like and then every next token inference is still like, you know, the sheer sum of everything all the way. It's plus all the context. It's up to date. And you could, I guess, theoretically steer that with you probably replace that with your steering. The only problem is steering typically is on one layer, maybe three layers like like you did. So it's like not exactly equivalent.Mark Bissell [00:32:33]: Right, right. There's sort of you need to get precise about, yeah, like how you sort of define steering and like what how you're modeling the setup. But yeah, I've got the paper pulled up here. Belief dynamics reveal the dual nature. Yeah. The title is Belief Dynamics Reveal the Dual Nature of Incompetence. And it's an exhibition of the practical context learning and activation steering. So Eric Bigelow, Dan Urgraft on the who are doing fellowships at Goodfire, Ekt Deep's the final author there.Myra Deng [00:32:59]: I think actually to your question of like, what is the production use case of steering? I think maybe if you just think like one level beyond steering as it is today. Like imagine if you could adapt your model to be, you know, an expert legal reasoner. Like in almost real time, like very quickly. efficiently using human feedback or using like your semantic understanding of what the model knows and where it knows that behavior. I think that while it's not clear what the product is at the end of the day, it's clearly very valuable. Thinking about like what's the next interface for model customization and adaptation is a really interesting problem for us. Like we have heard a lot of people actually interested in fine-tuning an RL for open weight models in production. And so people are using things like Tinker or kind of like open source libraries to do that, but it's still very difficult to get models fine-tuned and RL'd for exactly what you want them to do unless you're an expert at model training. And so that's like something we'reShawn Wang [00:34:06]: looking into. Yeah. I never thought so. Tinker from Thinking Machines famously uses rank one LoRa. Is that basically the same as steering? Like, you know, what's the comparison there?Mark Bissell [00:34:19]: Well, so in that case, you are still applying updates to the parameters, right?Shawn Wang [00:34:25]: Yeah. You're not touching a base model. You're touching an adapter. It's kind of, yeah.Mark Bissell [00:34:30]: Right. But I guess it still is like more in parameter space then. I guess it's maybe like, are you modifying the pipes or are you modifying the water flowing through the pipes to get what you're after? Yeah. Just maybe one way.Mark Bissell [00:34:44]: I like that analogy. That's my mental map of it at least, but it gets at this idea of model design and intentional design, which is something that we're, that we're very focused on. And just the fact that like, I hope that we look back at how we're currently training models and post-training models and just think what a primitive way of doing that right now. Like there's no intentionalityShawn Wang [00:35:06]: really in... It's just data, right? The only thing in control is what data we feed in.Mark Bissell [00:35:11]: So, so Dan from Goodfire likes to use this analogy of, you know, he has a couple of young kids and he talks about like, what if I could only teach my kids how to be good people by giving them cookies or like, you know, giving them a slap on the wrist if they do something wrong, like not telling them why it was wrong or like what they should have done differently or something like that. Just figure it out. Right. Exactly. So that's RL. Yeah. Right. And, and, you know, it's sample inefficient. There's, you know, what do they say? It's like slurping feedback. It's like, slurping supervision. Right. And so you'd like to get to the point where you can have experts giving feedback to their models that are, uh, internalized and, and, you know, steering is an inference time way of sort of getting that idea. But ideally you're moving to a world whereVibhu Sapra [00:36:04]: it is much more intentional design in perpetuity for these models. Okay. This is one of the questions we asked Emmanuel from Anthropic on the podcast a few months ago. Basically the question, was you're at a research lab that does model training, foundation models, and you're on an interp team. How does it tie back? Right? Like, does this, do ideas come from the pre-training team? Do they go back? Um, you know, so for those interested, you can, you can watch that. There wasn't too much of a connect there, but it's still something, you know, it's something they want toMark Bissell [00:36:33]: push for down the line. It can be useful for all of the above. Like there are certainly post-hocVibhu Sapra [00:36:39]: use cases where it doesn't need to touch that. I think the other thing a lot of people forget is this stuff isn't too computationally expensive, right? Like I would say, if you're interested in getting into research, MechInterp is one of the most approachable fields, right? A lot of this train an essay, train a probe, this stuff, like the budget for this one, there's already a lot done. There's a lot of open source work. You guys have done some too. Um, you know,Shawn Wang [00:37:04]: There's like notebooks from the Gemini team for Neil Nanda or like, this is how you do it. Just step through the notebook.Vibhu Sapra [00:37:09]: Even if you're like, not even technical with any of this, you can still make like progress. There, you can look at different activations, but, uh, if you do want to get into training, you know, training this stuff, correct me if I'm wrong is like in the thousands of dollars, not even like, it's not that high scale. And then same with like, you know, applying it, doing it for post-training or all this stuff is fairly cheap in scale of, okay. I want to get into like model training. I don't have compute for like, you know, pre-training stuff. So it's, it's a very nice field to get into. And also there's a lot of like open questions, right? Um, some of them have to go with, okay, I want a product. I want to solve this. Like there's also just a lot of open-ended stuff that people could work on. That's interesting. Right. I don't know if you guys have any calls for like, what's open questions, what's open work that you either open collaboration with, or like, you'd just like to see solved or just, you know, for people listening that want to get into McInturk because people always talk about it. What are, what are the things they should check out? Start, of course, you know, join you guys as well. I'm sure you're hiring.Myra Deng [00:38:09]: There's a paper, I think from, was it Lee, uh, Sharky? It's open problems and, uh, it's, it's a bit of interpretability, which I recommend everyone who's interested in the field. Read. I'm just like a really comprehensive overview of what are the things that experts in the field think are the most important problems to be solved. I also think to your point, it's been really, really inspiring to see, I think a lot of young people getting interested in interpretability, actually not just young people also like scientists to have been, you know, experts in physics for many years and in biology or things like this, um, transitioning into interp, because the barrier of, of what's now interp. So it's really cool to see a number to entry is, you know, in some ways low and there's a lot of information out there and ways to get started. There's this anecdote of like professors at universities saying that all of a sudden every incoming PhD student wants to study interpretability, which was not the case a few years ago. So it just goes to show how, I guess, like exciting the field is, how fast it's moving, how quick it is to get started and things like that.Mark Bissell [00:39:10]: And also just a very welcoming community. You know, there's an open source McInturk Slack channel. There are people are always posting questions and just folks in the space are always responsive if you ask things on various forums and stuff. But yeah, the open paper, open problems paper is a really good one.Myra Deng [00:39:28]: For other people who want to get started, I think, you know, MATS is a great program. What's the acronym for? Machine Learning and Alignment Theory Scholars? It's like the...Vibhu Sapra [00:39:40]: Normally summer internship style.Myra Deng [00:39:42]: Yeah, but they've been doing it year round now. And actually a lot of our full-time staff have come through that program or gone through that program. And it's great for anyone who is transitioning into interpretability. There's a couple other fellows programs. We do one as well as Anthropic. And so those are great places to get started if anyone is interested.Mark Bissell [00:40:03]: Also, I think been seen as a research field for a very long time. But I think engineering... I think engineers are sorely wanted for interpretability as well, especially at Goodfire, but elsewhere, as it does scale up.Shawn Wang [00:40:18]: I should mention that Lee actually works with you guys, right? And in the London office and I'm adding our first ever McInturk track at AI Europe because I see this industry applications now emerging. And I'm pretty excited to, you know, help push that along. Yeah, I was looking forward to that. It'll effectively be the first industry McInturk conference. Yeah. I'm so glad you added that. You know, it's still a little bit of a bet. It's not that widespread, but I can definitely see this is the time to really get into it. We want to be early on things.Mark Bissell [00:40:51]: For sure. And I think the field understands this, right? So at ICML, I think the title of the McInturk workshop this year was actionable interpretability. And there was a lot of discussion around bringing it to various domains. Everyone's adding pragmatic, actionable, whatever.Shawn Wang [00:41:10]: It's like, okay, well, we weren't actionable before, I guess. I don't know.Vibhu Sapra [00:41:13]: And I mean, like, just, you know, being in Europe, you see the Interp room. One, like old school conferences, like, I think they had a very tiny room till they got lucky and they got it doubled. But there's definitely a lot of interest, a lot of niche research. So you see a lot of research coming out of universities, students. We covered the paper last week. It's like two unknown authors, not many citations. But, you know, you can make a lot of meaningful work there. Yeah. Yeah. Yeah.Shawn Wang [00:41:39]: Yeah. I think people haven't really mentioned this yet. It's just Interp for code. I think it's like an abnormally important field. We haven't mentioned this yet. The conspiracy theory last two years ago was when the first SAE work came out of Anthropic was they would do like, oh, we just used SAEs to turn the bad code vector down and then turn up the good code. And I think like, isn't that the dream? Like, you know, like, but basically, I guess maybe, why is it funny? Like, it's... If it was realistic, it would not be funny. It would be like, no, actually, we should do this. But it's funny because we know there's like, we feel there's some limitations to what steering can do. And I think a lot of the public image of steering is like the Gen Z stuff. Like, oh, you can make it really love the Golden Gate Bridge, or you can make it speak like Gen Z. To like be a legal reasoner seems like a huge stretch. Yeah. And I don't know if that will get there this way. Yeah.Myra Deng [00:42:36]: I think, um, I will say we are announcing. Something very soon that I will not speak too much about. Um, but I think, yeah, this is like what we've run into again and again is like, we, we don't want to be in the world where steering is only useful for like stylistic things. That's definitely not, not what we're aiming for. But I think the types of interventions that you need to do to get to things like legal reasoning, um, are much more sophisticated and require breakthroughs in, in learning algorithms. And that's, um...Shawn Wang [00:43:07]: And is this an emergent property of scale as well?Myra Deng [00:43:10]: I think so. Yeah. I mean, I think scale definitely helps. I think scale allows you to learn a lot of information and, and reduce noise across, you know, large amounts of data. But I also think we think that there's ways to do things much more effectively, um, even, even at scale. So like actually learning exactly what you want from the data and not learning things that you do that you don't want exhibited in the data. So we're not like anti-scale, but we are also realizing that scale is not going to get us anywhere. It's not going to get us to the type of AI development that we want to be at in, in the future as these models get more powerful and get deployed in all these sorts of like mission critical contexts. Current life cycle of training and deploying and evaluations is, is to us like deeply broken and has opportunities to, to improve. So, um, more to come on that very, very soon.Mark Bissell [00:44:02]: And I think that that's a use basically, or maybe just like a proof point that these concepts do exist. Like if you can manipulate them in the precise best way, you can get the ideal combination of them that you desire. And steering is maybe the most coarse grained sort of peek at what that looks like. But I think it's evocative of what you could do if you had total surgical control over every concept, every parameter. Yeah, exactly.Myra Deng [00:44:30]: There were like bad code features. I've got it pulled up.Vibhu Sapra [00:44:33]: Yeah. Just coincidentally, as you guys are talking.Shawn Wang [00:44:35]: This is like, this is exactly.Vibhu Sapra [00:44:38]: There's like specifically a code error feature that activates and they show, you know, it's not, it's not typo detection. It's like, it's, it's typos in code. It's not typical typos. And, you know, you can, you can see it clearly activates where there's something wrong in code. And they have like malicious code, code error. They have a whole bunch of sub, you know, sub broken down little grain features. Yeah.Shawn Wang [00:45:02]: Yeah. So, so the, the rough intuition for me, the, why I talked about post-training was that, well, you just, you know, have a few different rollouts with all these things turned off and on and whatever. And then, you know, you can, that's, that's synthetic data you can kind of post-train on. Yeah.Vibhu Sapra [00:45:13]: And I think we make it sound easier than it is just saying, you know, they do the real hard work.Myra Deng [00:45:19]: I mean, you guys, you guys have the right idea. Exactly. Yeah. We replicated a lot of these features in, in our Lama models as well. I remember there was like.Vibhu Sapra [00:45:26]: And I think a lot of this stuff is open, right? Like, yeah, you guys opened yours. DeepMind has opened a lot of essays on Gemma. Even Anthropic has opened a lot of this. There's, there's a lot of resources that, you know, we can probably share of people that want to get involved.Shawn Wang [00:45:41]: Yeah. And special shout out to like Neuronpedia as well. Yes. Like, yeah, amazing piece of work to visualize those things.Myra Deng [00:45:49]: Yeah, exactly.Shawn Wang [00:45:50]: I guess I wanted to pivot a little bit on, onto the healthcare side, because I think that's a big use case for you guys. We haven't really talked about it yet. This is a bit of a crossover for me because we are, we are, we do have a separate science pod that we're starting up for AI, for AI for science, just because like, it's such a huge investment category and also I'm like less qualified to do it, but we actually have bio PhDs to cover that, which is great, but I need to just kind of recover, recap your work, maybe on the evil two stuff, but then, and then building forward.Mark Bissell [00:46:17]: Yeah, for sure. And maybe to frame up the conversation, I think another kind of interesting just lens on interpretability in general is a lot of the techniques that were described. are ways to solve the AI human interface problem. And it's sort of like bidirectional communication is the goal there. So what we've been talking about with intentional design of models and, you know, steering, but also more advanced techniques is having humans impart our desires and control into models and over models. And the reverse is also very interesting, especially as you get to superhuman models, whether that's narrow superintelligence, like these scientific models that work on genomics, data, medical imaging, things like that. But down the line, you know, superintelligence of other forms as well. What knowledge can the AIs teach us as sort of that, that the other direction in that? And so some of our life science work to date has been getting at exactly that question, which is, well, some of it does look like debugging these various life sciences models, understanding if they're actually performing well, on tasks, or if they're picking up on spurious correlations, for instance, genomics models, you would like to know whether they are sort of focusing on the biologically relevant things that you care about, or if it's using some simpler correlate, like the ancestry of the person that it's looking at. But then also in the instances where they are superhuman, and maybe they are understanding elements of the human genome that we don't have names for or specific, you know, yeah, discoveries that they've made that that we don't know about, that's, that's a big goal. And so we're already seeing that, right, we are partnered with organizations like Mayo Clinic, leading research health system in the United States, our Institute, as well as a startup called Prima Menta, which focuses on neurodegenerative disease. And in our partnership with them, we've used foundation models, they've been training and applied our interpretability techniques to find novel biomarkers for Alzheimer's disease. So I think this is just the tip of the iceberg. But it's, that's like a flavor of some of the things that we're working on.Shawn Wang [00:48:36]: Yeah, I think that's really fantastic. Obviously, we did the Chad Zuckerberg pod last year as well. And like, there's a plethora of these models coming out, because there's so much potential and research. And it's like, very interesting how it's basically the same as language models, but just with a different underlying data set. But it's like, it's the same exact techniques. Like, there's no change, basically.Mark Bissell [00:48:59]: Yeah. Well, and even in like other domains, right? Like, you know, robotics, I know, like a lot of the companies just use Gemma as like the like backbone, and then they like make it into a VLA that like takes these actions. It's, it's, it's transformers all the way down. So yeah.Vibhu Sapra [00:49:15]: Like we have Med Gemma now, right? Like this week, even there was Med Gemma 1.5. And they're training it on this stuff, like 3d scans, medical domain knowledge, and all that stuff, too. So there's a push from both sides. But I think the thing that, you know, one of the things about McInturpp is like, you're a little bit more cautious in some domains, right? So healthcare, mainly being one, like guardrails, understanding, you know, we're more risk adverse to something going wrong there. So even just from a basic understanding, like, if we're trusting these systems to make claims, we want to know why and what's going on.Myra Deng [00:49:51]: Yeah, I think there's totally a kind of like deployment bottleneck to actually using. foundation models for real patient usage or things like that. Like, say you're using a model for rare disease prediction, you probably want some explanation as to why your model predicted a certain outcome, and an interpretable explanation at that. So that's definitely a use case. But I also think like, being able to extract scientific information that no human knows to accelerate drug discovery and disease treatment and things like that actually is a really, really big unlock for science, like scientific discovery. And you've seen a lot of startups, like say that they're going to accelerate scientific discovery. And I feel like we actually are doing that through our interp techniques. And kind of like, almost by accident, like, I think we got reached out to very, very early on from these healthcare institutions. And none of us had healthcare.Shawn Wang [00:50:49]: How did they even hear of you? A podcast.Myra Deng [00:50:51]: Oh, okay. Yeah, podcast.Vibhu Sapra [00:50:53]: Okay, well, now's that time, you know.Myra Deng [00:50:55]: Everyone can call us.Shawn Wang [00:50:56]: Podcasts are the most important thing. Everyone should listen to podcasts.Myra Deng [00:50:59]: Yeah, they reached out. They were like, you know, we have these really smart models that we've trained, and we want to know what they're doing. And we were like, really early that time, like three months old, and it was a few of us. And we were like, oh, my God, we've never used these models. Let's figure it out. But it's also like, great proof that interp techniques scale pretty well across domains. We didn't really have to learn too much about.Shawn Wang [00:51:21]: Interp is a machine learning technique, machine learning skills everywhere, right? Yeah. And it's obviously, it's just like a general insight. Yeah. Probably to finance too, I think, which would be fun for our history. I don't know if you have anything to say there.Mark Bissell [00:51:34]: Yeah, well, just across the science. Like, we've also done work on material science. Yeah, it really runs the gamut.Vibhu Sapra [00:51:40]: Yeah. Awesome. And, you know, for those that should reach out, like, you're obviously experts in this, but like, is there a call out for people that you're looking to partner with, design partners, people to use your stuff outside of just, you know, the general developer that wants to. Plug and play steering stuff, like on the research side more so, like, are there ideal design partners, customers, stuff like that?Myra Deng [00:52:03]: Yeah, I can talk about maybe non-life sciences, and then I'm curious to hear from you on the life sciences side. But we're looking for design partners across many domains, language, anyone who's customizing language models or trying to push the frontier of code or reasoning models is really interesting to us. And then also interested in the frontier of modeling. There's a lot of models that work in, like, pixel space, as we call it. So if you're doing world models, video models, even robotics, where there's not a very clean natural language interface to interact with, I think we think that Interp can really help and are looking for a few partners in that space.Shawn Wang [00:52:43]: Just because you mentioned the keyword

Tales of Three Campaign OneArc 2.2: PoletoniaEpisode 70: Back on the Road - AgainTUO begins their journey to Poletonia. Elara and Ivy hitch a ride, Véres hears some gossip, and they give some advice to an aspiring adventurer.Content Warnings: Rumor mill, talk of deceased loves ones within rumor mill, toxic and complicated romantic relationships, brief electrocution, goo retrieval, reference to nightmares, romantic and sexual relationships, and profanity.Tales of Three is an all-queer, dark fantasy dnd podcast where your three Game Masters are also your three Players!If you like what you hear please tell your friends about us & consider giving us a 5 star review! It's a quick and easy way to show your support for small creators whose content you enjoy!Follow the Cast:Arianna as Elara SpinelsparkDusty as Ivy Nightbreeze-TinkerfeyWayra as VéresFind our socials here!Want to chat with the cast, talk spoilers, play games, and make new friends? Join our Discord!If you want to help keep the podcast running and get access to bonus content check out our Patreon or buy us a coffee on Ko-fi!Special thanks to SG for theme song, Chriss for the logo, Fenn & Ely for the character art!Background music and SFX by Epidemic Sounds & Monument Studios.

244 - Michael Sweet (Solo, Stryper, Boston) In episode 244 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with singer and guitarist Michael Sweet most recognizable from his band Stryper but also was in the band Boston and Sweet and Lynch among other projects. In their conversation Michael tells us why a solo album… it's his 11th solo album and tour plans behind the album. Michael discusses his home in Massachusetts and his time as the worship leader at his home church. Michael takes us through his youth in Southern California and his original band Rox Regime that played a lot with the hair bands whose names we all know and the transformation to Stryper. Michael takes us through his gear through the years and his obsession with tone and how the yellow and black color scheme came about and the guitars he's currently playing Sully electrics and Godin acoustics. Michael talks about his guitar hero's early on and he talks about his home studio as well as the studio where the band tracks and mixes… and he talks about his production work for his band. Michael takes us through his work with George Lynch and the band Boston and the possibilities of working with them again. Michael talks about the future of Stryper and the logistics of getting the band together with all the members living around the country and he talks tour plans. To find out more about Michael you can go to his website: michaelsweet.com Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #MichaelSweet #Stryper #Boston #SullyGuitars #TheMasterPlan #JamesPatrickRegan #SweetandLynch #theDeadlies #MarshallAmplifiers #RoxRegime #haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

Frank is joined by Guest Host Kate Willaert, author, historian, and YouTuber, to interview Jeremy Parish, media curator at Limited Run Games, author, YouTuber, and podcaster. Jeremy has a series of “Works” books and videos as part of a massive project to chronologize the 8-bit era. Jeremy's work covers various consoles, including Game Boy, NES, SG-1000, and Famicom, highlighting the significance of third-party developers and the impact of the NES on game design. We share a universal complaint of the challenges of maintaining a comprehensive and accurate release list for systems like the SG-1000 and the importance of community feedback in refining our work. The conversation touches on the potential for both future projects and genre-specific series, such as Metroidvania and Shmup games.You can listen to the Video Game History Hour every other Wednesday on Patreon (one day early at the $5 tier and above), on Spotify, or on our website.Mentioned in the show: Jaws Retro Edition (pre-orders closed): https://limitedrungames.com/collections/all-in-production/products/jaws-retro-edition-bigger-boat-edition-switch-ps5?_pos=3&_sid=a0a6bd1b1&_ss=r See more from Jeremy Parish:Bluesky: @jparish.bsky.social Youtube: @JeremyParish Podcast: patreon.com/retronauts Website: limitedrungames.com  See more from Kate Willaert:Bluesky: @katewillaert.bsky.socialYouTube: /a critical hitWebsite: acriticalhit.comPatreon: /acriticalhitVideo Game History Foundation:Email: podcast@gamehistory.orgWebsite: gamehistory.orgSupport us on Patreon: /gamehistoryorg

How do you keep growing fast without breaking your business?In this Owned and Operated supercut, John Wilson pulls together his favorite moments from recent conversations on what actually snaps when you scale: cash, leadership bandwidth, and the frontline experience that drives revenue.You'll hear why growth is expensive (in trucks, infrastructure, and overhead), how disciplined operators reinvest instead of upgrading their lifestyle too early, and why “the war is won inside the home” no matter how good your dashboards look.If you're running HVAC, plumbing, electrical, or roofing and feeling the strain of growth, this episode gives you the frameworks—and the hard truths—to keep momentum without chaos.In this episode, you'll learn:Why growth consumes cash (and how to plan for it)The “overhead body” you must build early: leadership, CX, SG&A, marketing, purchasingHow owners stall out by pulling cash too early (the lifestyle trap)Why playbooks beat ego: don't reinvent the wheel (Nexstar and more)Why frontline obsession matters more than dashboardsHow onboarding + clear pay plans create a culture that performsConnect: John Wilson: https://x.com/WilsonCompanies

Once you reach a certain level, there is no ‘better'…it's different.”   Released on August 19, 1983, FLICK OF THE SWITCH (the 9th studio album by AC/DC and the 3rd featuring Brian Johnson on the mic) is what some fans might call their “White Album” (arriving after their “Black Album” and “Bronze Album”, respectively), showing a black and white grayscale drawing of a lone Angus pulling down some massive power, so to speak.   “That's literally ‘Bad To The Bone' and ‘In My Time Of Dying'…”   While self-produced by the band and containing a much rawer production and drier mix than the ultra-produced Mutt Lange masterpieces which came before it, FLICK OF THE SWITCH is a back-to-basics approach showing the band embracing more of their earlier blues based sound while still remaining faithful to the signature, high-energy, up-tempo jams which have become their calling card. It's loud, straight ahead, and powerful, and while perhaps not as uber popular as the 3 albums that preceded it, FLICK is still very much an important album in the AC/DC catalog and one that would serve as a “connector” between where they had been and where they were headed.   “We could have a rated R show…it doesn't have to be X…”   We're finally back on track after getting derailed by the weather. Always remember to “wait ‘til it has some viscosity to it…” and then JOIN US for a “night time” dive into the album that would serve as the bridge into the next era of AC/DC with “The White Album” known as FLICK OF THE SWITCH.   Visit www.metalnerdery.com/podcast for more on this episode Help Support Metal Nerdery https://www.patreon.com/metalnerderypodcast Leave us a Voicemail to be played on a future episode: 980-666-8182 Metal Nerdery Tees and Hoodies – metalnerdery.com/merch and kindly leave us a review and/or rating on your favorite Podcast app Follow us on the Socials: Facebook - Instagram - TikTok Email: metalnerdery@gmail.com Can't be LOUD Enough Playlist on Spotify Metal Nerdery Munchies on YouTube @metalnerderypodcast More ACDC Episodes: https://www.metalnerdery.com/acdc   Show Notes: (00:01): #selfconsciousness / “Hold on…you don't know what you're asking for…”/ #darkcomedy / “It's kinda like…being in a cover band and having you guys show up when we play #POISON…”/ #carriesunderwear / “I need a rage truck…”/ “I like doing it…it's fun…”/ “A little bit…only if you push back…”/ ***WARNING: #listenerdiscretionisadvised ***/  “Synching up…locking in…”/ ***WELCOME BACK TO THE METAL NERDERY PODCAST (NIGHT TIME EDITION) ***/ #coveryourmouth / “I'm building up my immunity system…”/ “It could have been me…”/ #AIDSFlu / “It takes a flu nap is what you're saying…”/ #homemadelube / “Wait til it has some viscosity to it…” (05:55): EMAIL US at metalnerdery@gmail.com & PATREON US at patreon.com/metalnerderypodcast / #HailToTheBenton / “Dude, the Hog Story is worth the price of admission…”/ “Oh yeah…when we get done…I need to show you guys something…”/ “It's like zazz and zhuzh…”/ #NWOOSTM / “Here's what I hate about Marshalls…”/ #Traitor REACTOR IV (Venomizer – 2016) / #1986 / #incomplete /  “You know what dude, that's the best #BackstreetBoys song…”/ #Enmy – LEDGE / #melody / “It's the hard stop…and then super soft…”/ #markthetime / “I wasn't expecting to like that…”/ “No Slayer of the Episode?”/ #anush #penish / #SlayerOfTheEpisode / #Slayer HALLOWED POINT (Seasons In The Abyss – 1990) / “And just like that…all is right in the world…”/ “It's all 7's…” (22:47): #TheDocket METAL NERDERY PODCAST PRESENTS:  AC/DC – FLICK OF THE SWITCH / #ACDC #TheWhiteAlbum / “I don't remember being 10 and listening to AC/DC…” “It's black and white in grayscale…”/ Released August 19, 1983 / “Doing AC/DC always takes me back to childhood…”/ “In the For…Flick…Fly category, Flick is in the middle there…” / “It's 3-D and you can feel the texture…”/ Recorded in Nassau, The Bahamas with Robert John “Mutt” Lange / “He's the Bob Rock of the 80's…”/ “Their sound is menopause…”/ RISING POWER / “I feel like it was a little slow to start…”/ “#Pyromania btw was January 20 (1983)…”/ “I don't know what that is: a desert vagina kinda…”/ THIS HOUSE IS ON FIRE / “They should have swapped those two…”/ “Mega ultra mother fucking super stardom…” (33:23): FLICK OF THE SWITCH / “I think every band has a ‘connector' album…”/ “That's a good episode…3 albums in a row…”/ “Use penal clean…”/ NERVOUS SHAKEDOWN “Two words…slower and sleazier…”/ “You know what the leading cause of death is for nymphomaniacs is?”/ “We could have a Rated R show…it doesn't have to be X…”/ #killercloser / LANDSLIDE / “What a great closer for Side 1…”/ “That riff…reminded me of this…”/ PLAYING WITH GIRLS (Fly On The Wall – 1985) / “I try to hold this thing together…” (38:38): GUNS FOR HIRE / “Turn this up to loud…” / “Once you reach a certain level, there is no ‘better'…it's just different.”/ DEEP IN THE HOLE / “I'm over A.I…”/  “I cup the balls, I go all the way…”   (45:34): BEDLAM IN BELGIUM / “Side 2 better than Side 1…” / “It's really close to ‘Fly On The Wall'…” / BADLANDS / “That's literally ‘Bad To The Bone' and ‘In My Time Of Dying'…”/ “I feel like he does that in the studio…”/ SG vs Les Paul / #markthetime / BRAINSHAKE / #killercloser / “That sounds like an AC/DC closer…”/ “It's only 8 minutes longer than Reign In Blood…”/ “It sounds like a good bridge to ‘Fly On The Wall'…”/ “It's the bridge between the old and the next…”/ Bands with great 3-album runs / THANK YOU FOR JOINING US!!!/ #untilthenext #outroreel

In der neuen Folge von 61 Meter spricht Michelle Potthast über ihren Weg von der ersten Hospitation bei der TuS Koblenz bis zur heutigen Co-Trainerin. Die hauptberufliche Lehrerin erzählt von den Anfängen in einem Neuwieder Stadtteil über ihre Zeit als Cheftrainerin der Frauen der SG 99 Andernach II in der Regionalliga Südwest bis hin zum aktuell laufenden A-Lizenz-Lehrgang sowie davon, was sie aus der täglichen Arbeit im TuS-Umfeld mitnimmt. Ein Gespräch über Lernen und Entwicklung, die Arbeit bei der TuS, den Frauenfußball und die Idee, jeden Tag ein kleines Stück besser zu werden.

NBA Trade Season woke up in a BIG way. Friend of the show Coach Andy Godnick joins to talk Harden for Garland, Jaren Jackson Jr to Utah, Vucevic to Boston and what more is to come for the trade deadline! For your main course: ranking the top 4 prospects in the upcoming NBA draft, which may be the best in recent memory. Details below...Timestamps: James Harden for Darius Garland reaction (2:33), Vucevic to Boston (14:00), Jaden Ivey to Chicago (18:40), JAREN JACKSON JR to UTAH (21:45)TOP NBA DRAFT PROSPECTS (39:00), Darryn Peterson's superstar SG potential (39:20), Cam Boozer: Star or Elite role player (48:00), Caleb Wilson: Our draft darling (1:02:20), AJ Dybantsa: Overhyped? (1:15:00)Thank you for listening. Follow/rate us here and on X @drewsemler and @maxklotz_

'n Gesprek wat jou nooi om saam te dink oor die skepping in al sy diversiteit. Pieter gesels met Helène Smit. “Kom ons gesels saam oor die prentjies wat ons het van mekaar wat ons nie eens altyd besef nie. Dalk help dit ons om saam die volheid van God se skepping te ontdek. Natuurlik is hierdie tipe gesprekke soms ongemaklik. En as jou huis en omgewing ‘n veilige spasie is waar jy nie regtig hoef te kies vir ongemak nie, kan ons dit maklik vermy. Maar verloor ons nie dan ‘n stuk van God se “voluit lewe” geskenk nie?” – Helène Luister hier na die klankopname of op die potgooi-platform van jou keuse. . . Die veelkleurige skepping beweeg my… – Helène Smit Hulle sê dat ‘n liefde vir voëlkyk jou onverhoeds betrap met die ouderdom. En aangesien ek groot geword het in ‘n familie met verkykers en voëlboeke, het die onvermydelike toe ook met my gebeur. Saam met die voëlkyk die laaste 10 jaar, het ek so diep onder die indruk gekom van die diversiteit van die skepping. Dit voel vir my al meer of God soveel pret gehad het toe hy al die verskillende voëls uitgedink het. Kyk net na die Paradysvlieevanger of Rooiborslaksman! En dan praat mens nog nie eens oor al die vreemde insekte, wonderlike fynbos en belaglike diepsee kreature nie! As ek kyk na al die verskillende persoonlikhede, eienskappe en talente van die mensdom, sien ek beslis ook God se kreatiwiteit en sin vir humor. Dit is dalk nie heeltemal teologies korrek nie, maar ek is oortuig God het die skepping so divers gemaak vir ons genot. Dan wonder ek: As ek kyk na die mense om my, die mense wat naby my bly, saam met my kerk toe gaan, dieselfde plekke oefen as ek, dan voel dit of hulle maar meestal lyk soos ek. Daar is beslis nie dieselfde diversiteit in my vriendekring as wat daar is in hierdie mooie dorp van ons nie. Ons weet almal dat dit is as gevolg van ons land se geskiedenis-storie. Maar dit voel of ek uitmis op ‘n groot stuk genot wat God dalk vir my beplan het. Want dink net hoe my prentjie van Hom sou kon verander as ek meer gereeld saam met iemand wat totaal anders as ek lyk en grootgeword het en dink, die Bybel kan lees! Maar sjoe – dis moeilik om regtig kontak te maak! Ons het soveel vooropgestelde idees oor mekaar. As ek iemand sien wat ek nie ken nie, maak ek aannames oor hulle op grond van geslag, ras, klere. En dit verander dadelik hoe wyd my arms oop is vir hulle. En of ek dalk ongemerk eerder seker maak my motordeur is gesluit in die verkeer… Ek sou beslis kon sê dat my wêreld heeltemal veelkleurig genoeg is met werk en gesin en vriende en stokperdjies en dat ek nie regtig die res van die skepping mis nie. Dit is mos nie regtig nodig om te gaan soek na nog meer kleure en geure en geluide nie? Is daar enige gevaar daarin om maar net dit wat ek reeds om my het, voluit te geniet? Dan dink ek egter aan die nuwe lied wat ek al harder en meer gereeld hoor wêreldwyd: Ek staan op vir MY mense. Ek maar seker dat MY mense OK is. Die Bybel sê ek moet lief wees vir my bure – so ek gaan veg vir my buurt. Ek dink egter dat ons dalk hier keuses begin maak wat kies teen ‘n deel van God se hart? Ek wonder wat sê die Bybel oor nationalisme? Oor menswees bo ras en taal en al die ander verskille en diversiteit. Daarom wil ek jou uitnooi om saam met my te dink oor die skepping in al sy diversiteit. Kom ons gesels saam oor die prentjies wat ons het van mekaar wat ons nie eens altyd besef nie. Dalk help dit ons om saam die volheid van God se skepping te ontdek. Natuurlik is hierdie tipe gesprekke soms ongemaklik. En as jou huis en omgewing ‘n veilige spasie is waar jy nie regtig hoef te kies vir ongemak nie, kan ons dit maklik vermy. Maar verloor ons nie dan ‘n stuk van God se “voluit lewe” geskenk nie? So hier is jou uitnodiging: kom gesels saam. In ‘n veilige spasie waar jy mag sê wat jy voel, al voel dit nie heeltemal reg nie. Kom ons ontdek ons dorp se volle kleure saam. Ek het dit n paar jaar terug begin doen. Ongemak gekies deur mense te volg op sosiale media wat my bitter kwaad maak. Spasies gekies waar mense anders lyk as ek. Boeke en TV reekse  deur mense van ander rasse en kulture as ek. Ek het diversiteit gekies! En wow – ek het sooooooveel gewen! En ek is boonop nou BAIE minder ongemaklik. Ek voel baie minder skuldig. Dit voel of ek tools het om verskil te maak. Kom kuier saam. Kom ontdek die volle geskenk van diversiteit en die God wat dit uitgedink en geskep het en steeds so lief het. Word deel van ons reis binne SG om met groter verwondering tuis te kom en te leef met diversiteit van mense in ons lewe: Versoeningsgesprek – 'n oop, veilige saam-gesels ruimte oor die wonders, uitdagings en misverstande oor ras en diversiteit. Donderdag 12 Feb om 18:30 by kantoor [elke 2e Do van die maand] Becoming human – 'n werkswinkel wat doelbewus geloof en diversiteit in gesprek bring met mekaar. Donderdag 26 Feb om 18:30 by die kantoor [elke laaste Do. van die maand] Church walk – 'n pelgrimstog deur die geskiedenis van Stellenbosch en ons storie.    Sat 21 Mrt 8:00-12:00, vanaf Aunt Sophie by die Ou Landbou-saal. Volg hierdie skakel om deel te word van die WA-groep

243 - Kurt Baker (solo, the Leftovers) In episode 243 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with bassist, guitarist and bandleader Kurt Baker. In their conversation Kurt tells us about living in Brooklyn and working for Little Steven's record label “Wicked Cool Records” a label that he's also recording for. Kurt discusses his new single and when he might release a new album and his style of Power Pop music. Kurt describes how he got hooked up with Wicked Cool and how he eventually started working for the label. Kurt tells us about living and playing his music in Spain before working for Little Steven. Kurt talks about his musical history growing up in Maine and his band “the Leftovers” (one of the first bands to do video blogs) and why that band disbanded and what made him go solo. Kurt describes his gear both his basses and his guitars and his Ampeg, Orange and VOX amps and he describes the backline situation in New York. To find out more about you can go to his socials as kurtmiltonbaker or his bandcamp page: kurtbaker.bandcamp.com and check out Kurt's music it's refreshing. Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #KurtBaker #theLeftovers #WickedCoolRecords #LittleStevensUndergroundGarage #FenderBass #EpiphoneGuitars #PrecisionBass #AmpegAmps #JamesPatrickRegan #theDeadlies #haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

Silvana, Eric and Tegan watch Stargate SG-1 Season 6 Episode 15 "Paradise Lost." The bromance between Jack and Colonel Maybourne is back with a vengeance. The queerbaiting is off the charts from the very beginning with the hot dog jokes. Maybourne springs his new plan to avoid being imprisoned and convinces the SGC to authorize a mission to a planet that he claims has a cache of goa'uld weapons. As expected, SG-1 is double crossed but Jack accidentally goes through a portal with Maybourne with no way to get back to the Stargate. Sam, Jonas and Teal'c are back on earth trying to find Jack with the not very helpful assistance of Dr. Bill Lee. There is a touching moment between Sam and Teal'c which acknowledges the loss of Daniel. What did you think of this episode? Join the conversation on our socials. Episode ratings: Comedic Effect - 7/7 chevrons Emotional Impact - 6/7 chevrons Enjoyability - 6/7 chevrons Culture/history/lore - 3/7 chevrons Novelty - 2/7 chevrons Technical Quality  - 5/7 chevrons Plot -5/7 chevrons Relevance to the overall story? Yes relevant, do not skip

Gate those stars! This week, Emily and V take a look at fannish campaigns to save beloved TV shows and beloved characters, focusing on one in particular: the campaign to bring Daniel Jackson back to Stargate SG-1. From mailing marshmallows to taking out ads in Variety and The Hollywood Reporter, fans have done all kinds of things to make their voices heard by TPTB. Were they successful in bringing back Daniel Jackson (and saving SG-1's premiere slash ship, natch)? Join us in our scifi spaceship to find out! Sources Fanlore Daniel Jackson Divas And again. Alison Grieves for Daniel Jackson and SG-1 Salon Emily's spreadsheet of fan campaigns! LIVE SHOW ANNOUNCEMENT! We'll be attending TGIF/F aka TGI Femslash, which is a small femslash fan con in southern California over Valentine's Day weekend in February. It'll be the con's ten-year anniversary, and they've asked us to do a special, live podcast episode about the history of the con as their special highlighted programming. If you love femslash and want to come meet us and be a part of this wonderful, small event, you should register! A 3-day pass starts at $120. You can register for the con and find lots more details at tgifemslash.com! Promo Codes Aim High Brooch Designs - For 25% off any order on Aim High Brooch Designs on Etsy, including a custom brooch, bag charm, keychain, or magnet design, use the promo code TWIFH. This Week In Fandom History is a fandom-centric podcast that tells you… what happened this week in fandom history! Follow This Week in Fandom History on Tumblr at @thisweekinfandomhistory You can support the show via our Patreon at http://www.patreon.com/thisweekinfandomhistory.  If you have a fannish company, event, or service and would like to sponsor or partner with TWIFH, please contact us via our website. Please remember to rate the show 5 stars on your listening platform of choice!

The cannabis industry is more competitive then it was 5-10 years ago. But that doesn't mean it's broken. In this episode, I talk with Jeff Wissink, Partner at Paladin Restructuring. We cover what's really happening inside cannabis businesses today. We cover what is forcing owners to rethink where they spend money, when to engage a restructuring professional and why growing through M&A is harder than it looks. The message is clear: the rules changed, and smart operators are adjusting.Jeff explains Paladin's two main ways of helping companies. Restructuring is for emergencies like missing payroll, missing debt covenants or running out of cash. Performance improvement is about fixing problems early so the business can make more profit and avoid a crisis. Using his past experience as a cannabis COO, Jeff shares why one simple number SG&A as a percent of revenue can show what's working and what's not. He also explains why cutting back too much on finance and HR can hurt growth. And why waiting until the last minute leaves very few good choices. We wrap up by talking about leadership, survival, and what comes next for cannabis. Jeff uses a fun example of kids all chasing the soccer ball to explain why clear roles matter as companies grow. He also breaks down why retail is costly and why strong operations matter more than hype. He is nice but honest, if owners and investors focus on cash flow, teamwork, and smart systems now, they'll be in a great spot when the industry settles down and new opportunities open up.

242 - Axel Ellis (the Runarounds, Ax and the Hatchetmen) In episode 242 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with Axel Ellis guitarist for the band/Amazon Prime Show “the Runarounds” and his band “Ax and the Hatchetmen”. In their conversation Axel gives us a little history of the band, a band that was cast for the Amazon show. Initially auditioning with his whole band for what they thought was a guest spot on an established show. Axel takes us through his musical history growing up in the suburbs of Chicago with parents that loved music and initially studying flamenco guitar before moving on to jazz and then rock. Axel describes how the show's characters mirrors his own start in music. Axel tells us about the benefits of being on a tv show, not just the fame and money, but the sponsorships from gear companies. Axel talks about his gear both for the Runarounds tv show, the bands tour that he's on now and for his other band “Ax and the Hatchetmen” Axel discusses the logistics for the band as far as being spread apart around the country for songwriting and rehearsals. Axel gives us his thoughts on his future of his band, the Runarounds band and the tv show's potential second season. To find out more about Axel you can go to his band website: axandthehatchetmen.com or the website for the Runarounds: therunarounds.com Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #AxelEllis #theRunarounds #AmazonPrimetheRunarounds #AxandtheHatchetmen #GretschGuitars #WhiteFalcon #SuproAmps #JamesPatrickRegan #theDeadlies #haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

In today's episode of Motley Fool Money, host Emily Flippen is joined by analysts Jason Hall and Asit Sharma to dive into three recent stories where the operating system underneath a business has started to matter more than the companies above it. They discuss: - Nvidia's $2 billion investment into CoreWeave and how AI infrastructure is colliding with physical constraints - How restaurant tech is pushing the limits on throughput - A rare-earth deal between private companies and the U.S. government highlighting what are issues of national security Companies discussed: NVDA, CRWV, TOST, SHOP, CAVA, SG, WING, USAR Host: Emily Flippen, Jason Hall, Asit Sharma Producer: Anand Chokkavelu Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

It's telling to hear NATO's future is not “guaranteed” according to a former NATO boss. After a jaw-dropping US threat to take Greenland shocked the world. President Trump's first year back in power is also overshadowing the United Nations' 80th milestone. Prompting calls to retool the world's top diplomat.  In this episode of Disorder, hosted by Mark Lobel, the former head of NATO tells Disorder we should make the United Nations Secretary-General the "chairman" of the Security Council. Brazil's former Ambassador to the United Nations says the role should be a single mandate term of six or seven years, "to retain the willingness to displease certain sources of power”. Recorded at a special UNA-UK event, George Robertson and Ambassador Antonio Patriota reveal how Donald Trump's disorderly approach is causing a major re-think of organisations and leadership in the world. Speaking in the same building that ushered in the United Nations General Assembly in 1946, exactly 80 years ago this month.  The Brazilian Ambassador to the UK didn't hold back ...  On Venezuela:  “I feel very uncomfortable as a South American to witness an intervention that is a flagrant violation of international law.”  On Nigel Farage joining climate talks:  “I don't think (he's) very eager to engage on this topic”  On presenting the Nobel Peace Prize to Trump:  “As a South American, I felt embarrassed by this gesture, because I don't think it enhances anybody's dignity to do that.”  Plus - George Robertson tips a British politician as the next big thing ... and it's not who you expect! Stay news of a special live event with Disorder and the UNA-UK for mega orderers, and to join our Mega Orderers Club and come along, and get ad-free listening, early release episodes, and bonus content, visit https://disorder.supportingcast.fm/  Producer: George McDonagh Subscribe to our Substack - https://natoandtheged.substack.com/ Disorder on YouTube - https://www.youtube.com/@DisorderShow Show Notes Links: You can get in touch with Mark, to host or speak at your event here: ⁠https://www.mark-lobel.com/getintouch⁠  To join our Mega Orderers Club in honour of Greg, for ad free listening and early release episodes, visit https://disorder.supportingcast.fm/ UNA UK website www.una.org.uk UN official article summarising the event - https://news.un.org/en/story/2026/01/1166783 Gordon Brown's call to action for democracies to reinvigorate the international order, highlighting the Attorney General's speech at the event - https://www.theguardian.com/commentisfree/2026/jan/20/donald-trump-greenland-world-plan-leadership Devex video interviews on Insta - https://news.un.org/en/story/2026/01/1166783 Sky News - 'Is the US attacking the UN's principles?' (Interview with the President of the General Assembly) https://news.sky.com/video/is-the-us-attacking-the-uns-principles-13495782  The Guardian - 'Guterres warns of ‘powerful forces' undermining ‘global cooperation.'' https://www.theguardian.com/world/2026/jan/17/antonio-guterres-warns-forces-undermining-global-cooperation-un-80th-anniversary-secretary-general-multilateralism-international-law  NPR - 'United Nations leaders bemoan global turmoil as the General Assembly turns 80.' https://www.npr.org/2026/01/18/nx-s1-5678366/united-nations-general-assembly-80-london#:~:text=LONDON — Just over 80 years,the importance of international cooperation.  Full speech by SG: https://webtv.un.org/en/asset/k1u/k1uo45t198 Learn more about your ad choices. Visit megaphone.fm/adchoices

What do Inception, Tim Robinson, Luis Buñuel, Woody Allen, and Chantal Akerman have in common? They all get compared to Hong Sang-soo's On the Beach at Night Alone in this episode of Deep Cut! Listen on as we unpack the movie that's loosely about Hong's and Kim Min-hee's career-changing relationship, digest more awkward dinner scenes, and discuss the merits of going to the beach in the winter.Links:Scold your friends for being inauthentic at our FREE patreon, discord server, and our socials @ www.deepcutpod.com Timestamps:00:00 Intro02:31 General reactions08:00 Context / Hong+Kim relationship14:32 SG public opinion survey18:04 Hong Sang-soo's 'Inception'20:08 Hong Sang-soo / Tim Robinson21:43 Hong / Buñuel25:45 Hong not planning era27:17 Ryan Swen Notarized and dinner scene33:16 What to do with this movie?38:13 Hong's Chantal Akerman41:10 Hong as Woody Allen

Yoo people in this weeks episode we have our bro on SG! We talk about what kind of parents we want to be, how we are planning to raise young black sons and SG talks us through how to rose to be senior footballing scout in the UK. We hope the Triple B Dry Jan Fast is going well. We're nearly at the end now, so let's keep pushing, keep sending in your videos, pictures, and messages, and let's finish strong! As always, any dilemmas or testimonies please send through !

Episode GuideMaul Shadow Lord Official Trailer Stargate SG-1 s05ep13 Proving Ground - ability to follow orders & instinctss05ep14 48 Hours - Overriding gate diagnosticss05ep15 Summit - Return of Anubis via proxys05ep16 Last Stand - Survival of the Tok'ras05ep17 Fail Safe - Anubus attacks Earth with a naquaah enhanced meteors05ep18 The Warrior - progress of the Jaffa rebellions05ep19 Menace - possible creator of the Replicatorss05ep20 The Sentinel - effects of teams pretending to be an SG teams05ep21 Meridian - Jonas Quinns05ep22 Revelations - Rise of Anubis and history of the Asgards06ep01 Redemption Part 1 - Anubis attacks Earth agains06ep02 Redemption Part 2 - Bra'tac, Teal'c and Rya'c attack Anubis' weapon built by the Ancientss06ep03 Descent - salvaging a motherships06ep04 Frozen - A real life Ancient frozen in times06ep05 Nightwalkers - variation of the Goa'uld powers without becoming ones06ep06 Abyss - Ba'als06ep07 Shadow Play - Trying to ally with Jonas' home but they're still fighting their battless06ep08 The Other Guys - 1st appearance of Harak, later seen with Anubiss06ep09 Allegiance - Human/Tok'ra/Jaffa alliances06ep10 Cure - Origins of the Tok'ra and the means of stopping the Jaffa reliance on symbiotess06ep11 Prometheus - X303 not the Enterprises06ep12 Unnatural Selection - Human form replicatorss06ep13 Sight Unseen - effects of Ancient devicess06ep14 Smoke & Mirrors - shadow organizations trying to control the Stargates06ep15 Paradise Lost - An all O'Neill and Mayborne episodes06ep16 Metamorphasis - More Niirti experimentss06ep17 Disclosure - Revealing the Stargate program and defeating Kinsey agains06ep18 Forsaken - escaped alienss06ep19 The Changeling - Teal'c without the his symbiote via tretonines06ep20 Memento - test flight of the Prometheuss06ep21 Prophecy - Niirti's experiment on Jonass06ep22 Full Circle - Attack and final rise of AnubisStar Wars KOTOR II The Sith Lords Jedi Guardian Android Gameplay GTA III Definitive Edition Doom II Hell on Earth LinksSupport my Youtube channel by becoming a member today!Blog Podcast YouTube Version Hosted on Acast. See acast.com/privacy for more information.

What does real faith look like under fire? Jeff Haecker, Lisa Jones, and Victor Lams unpack sacrifice, belief, and resistance as SG-1 tests dangerous tech, Vala challenges false gods, and the Ori reveal their true nature. The post Line in the Sand (SG1) appeared first on StarQuest Media.

Dial the Gate is privileged to welcome Stargate SG-1 Executive Producer and Writer Michael Greenburg to learn all about his career, his years on MacGyver, and his experience on the set of SG-1.

Fast casual restaurant stocks were hit hard over the past year, but many have snapped back over the past month. In today's episode of Motley Fool Money, Emily Flippen is joined by Fool analysts Sanmeet Deo and Jason Hall to break down what has caused the rebound, how consumer tastes have changed, and if fast casual stocks are set up for continued strong performance in the year ahead. Companies discussed: CAVA, CMG, SG, WING, EAT, SBUX, MAMA, JBFCF, YUM Host: Emily Flippen, Sanmeet Deo, Jason Hall Producer: Anand Chokkavelu Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

241 - Boy Golden In episode 241 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with singer/songwriter and producer Boy Golden aka Liam Duncan. In their conversation Liam describes his upcoming tour schedule in Canada and growing up in rural Manitoba in the cold. Liam talks gear, his guitars and amps and his collection of Russian microphones and a special guitar labeled Garnet after the amp maker. Liam tells us about his earlier band “the Middle Coast” before he went out as Boy Golden and he explains the Boy Golden moniker. Liam talks about his time as the keyboardist for the Bros. Landreth and his influences early on. Liam discusses his new album “Best of Our Possible Lives” and the personal on the album and he also describes his home studio. To find out more about Boy Golden you can go to his website: boygolden.ca Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #BoyGolden #theMiddleCoast #LiamDuncan #Manitoba #theBrosLandreth #YamahaGuitars #JamesPatrickRegan #BestofOurPossibleLives #theDeadlies #HomeStudio #haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

In most companies, budget season is a predictable exercise in "incrementalism," taking last year's numbers and adding a 5% bump. But what happens when leadership drops a bomb and says, "This year, we start from zero"?In this episode of Corporate Finance Explained on FinPod, we explore Zero-Based Budgeting (ZBB), a high-stakes financial framework in which every dollar must earn its right to exist. We unpack the mechanics of ZBB, the "Save to Grow" mindset, and the cautionary tales of companies that saved themselves into obsolescence.ZBB vs. Traditional Budgeting: The Logic FlipThe fundamental difference between ZBB and the status quo is a shift in perspective:Traditional Budgeting: Asks, "How much more or less do we need than last year?" It is comfortable, based on precedent, and often hides "historical entitlement."Zero-Based Budgeting: Asks, "If we were building this function from scratch today, what would we actually fund?" It treats every expense as discretionary and requires a strategic justification for every line item.The Mechanics: Decision Packages and Tiered FundingThe core engine of a successful ZBB program is the Decision Package. Rather than funding a department, leadership funds specific activities using a three-tiered approach:Minimum Level: The "keep the lights on" spend. The bare minimum required for operations and regulatory compliance. Current Level: Business-as-usual spending. Enhanced Level: Discretionary funding for innovation, R&D, and new customer acquisition.This framework allows leadership to make strategic trade-offs. For example, funding a "minimum" level for administration to prioritize "enhanced" funding for revenue-driving marketing.Case Studies: The Scalpel vs. The AxeKraft Heinz (The Warning): Following a 2015 merger, the company applied a "ruthless" ZBB model. While margins shot up instantly, they cut too deeply into R&D and brand-building. The result was massive brand erosion and billions in write-downs. Unilever (The Blueprint): In response to market pressure, Unilever adopted a "Save to Grow" ZBB model. They targeted specific SG&A categories but "ring-fenced" strategic areas like innovation. Savings were immediately reinvested in the business, proving that ZBB can be a tool for growth, not just austerity.The Role of FP&A: From Scorekeeper to ArchitectWithout a strong Financial Planning & Analysis (FP&A) team, ZBB is just a spreadsheet exercise. In a ZBB environment, FP&A professionals must:Define Cost Drivers: Moving away from "last year's bill" to metrics like transaction volume or headcount.Assign Ownership: Ensuring the person who owns the activity is the one defending the spend.Differentiate Costs: Protecting "Change the Business" costs (future investments) from being swallowed by "Run the Business" costs (daily operations).

This Sunday school lesson talks about the power of bold and humble prayers. What I keyed in on was how Abraham used that power. Genesis 18:16-25 God has a role for Abraham and his family to play in his plan—a ministry. This is the first time he brings him into it. S&G are unjust and cruel. Abraham advocates…

Tales of Three Campaign OneArc 2.1: OladellEpisode 69: A Gift and a Departure Join us as we say goodbye to Oladell! Our trio accept a gift from Velrith and head off on their next adventure.Content Warnings: Reference to alcohol consumption and being drunk, and Profanity Tales of Three is an all-queer, dark fantasy dnd podcast where your three Game Masters are also your three Players!If you like what you hear please tell your friends about us & consider giving us a 5 star review! It's a quick and easy way to show your support for small creators whose content you enjoy!Follow the Cast:Arianna as Elara SpinelsparkDusty as Ivy Nightbreeze-TinkerfeyWayra as VéresFind our socials here!Want to chat with the cast, talk spoilers, play games, and make new friends? Join our Discord!If you want to help keep the podcast running and get access to bonus content check out our Patreon or buy us a coffee on Ko-fi!Special thanks to SG for theme song, Chriss for the logo, Fenn & Ely for the character art!Background music and SFX by Epidemic Sounds & Monument Studios.This week we're featuring our friends at Somebody's Heroes Podcast. Check out their podcast here!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

240 - Joel Hoekstra In episode 240 of “Have Guitar Will Travel”, presented by Vintage Guitar Magazine, host James Patrick Regan speaks with guitarist Joel Hoekstra, in their conversation Joel describes living in New York City and growing up in the suburbs of Chicago with his parents who were both classical musicians and Joel tells us why he didn't pursue piano. Joel describes the impact of seeing AC/DC on MTV as a kid which slowed his sports interests. Joel describes his gear starting on his stepmom's guitar and he discusses his guitars from then on… and how he got the collecting bug and he discusses his custom Gibson's and Jackson's and the guitars he uses for each of his gigs. Joel tells us about his first bands through his gigs with Trans Siberian Orchestra, Whitesnake, Night Ranger, Jim Peterik, Cher… as well as his time spent as a pit guitarist for Broadway shows like Rock of Ages and Love Janis. Joel talks about using in-ear monitors and hearing loss and Joel talks about his time at GIT in Hollywood and working at Cherokee Studios. Joel discusses his new album “From the Fade” and the personal on the album and the chances for a tour and he describes the other projects he's working on: Revolution Saints, Hoekstra Gives, teaching remote lessons, Broadway's Rock of Ages band and Iconic (which includes a lot of his former Whitesnake bandmates as well as time spent producing other artists. Finally Joel tells us about what he does when he's not playing guitar… his kids, and anything to escape music and plans to go to NAMM next week. To find out more about Joel you can go to his website: joelhoekstra.com Please subscribe, like, comment, share and review this podcast! #VintageGuitarMagazine #JoelHoekstra #Whitesnake #TransSiberianOrchestra #JacksonGuitars #GibsonCustomShop #JamesPatrickRegan #FromtheFade #theDeadlies #NightRanger #RockofAges #Hoekstra13#haveguitarwilltravelpodcast #HGWT #tourlife Please like, comment, and share this podcast! Download Link

Season 6 Episode 21: Prophecy Jonas Quinn aka Corin Nemec tries to impress the Gang one final time by developing PreCog Abilities that can save them from certain disaster.  As they're trying to figure the situation on a super poor planet with bad food but some decent Naquadah reserves, the Gang decide to forget about the last six season, and just not listen to the man.   Teal'c, you forget about the invisible bugs episode!?  CARTER, YOU WERE A FREAKIN GOTHIC COMPUTER AI!!  But precog abilities?  Impossible!   Daddy Hammond finally believes him, and through some weird machinations of quantum mechanics, his future predictions don't come true, and the mountain base and the poor planet are saved.  Unfortunately, we can't say the same for the character of Jonas, and Corin Nemec's future with SG-1.   It sucks.   ----more---- 00:00 - Intro 6:08 - 24 Seconds 7:53 - Episode Debrief 1:09:03 - Were We Comforted 1:10:50 - Yeh Neh or Meh 1:14:00 - Next Episode 1:16:13 - ComeTrya! 1:17:25 - Get To Know Your Hosts 1:19:36 - Outro  

Shoot us a Text.Episode #1241: CarMax leans on price cuts and marketing to spark sales, Toyota takes its iconic Hilux electric in Europe, and Walmart keeps scaling drone delivery as demand grows.CarMax is shifting back to fundamentals as sales and earnings continue to slide. The company will cut prices, trim costs, and increase marketing to regain momentum heading into 2026.Q3 results saw unit sales down 8% and earnings down 50% year-over-year.CarMax will use targeted price cuts to spark demand, not blanket reductions.The company is lowering margins while boosting marketing to drive traffic.SG&A will be cut by $150M annually despite increased ad spend.“Our average selling prices have drifted upward and appear to be less attractive to customers,” said Interim CEO David McCreight.Toyota just electrified one of its most important global trucks. The Hilux made its first European appearance as a full EV, signaling Toyota's pickup electrification push—just not for North American buyers.Toyota debuted the Hilux BEV at the Brussels Motor Show, and uses a 59.2 kWh battery, offering up to 160 miles WLTP range, or 236 miles in city driving.With AWD and 473 Nm of torque, it can tow 1.6 tons and haul over 1,500 lbs, keeping its work-truck credibility.Europe gets the Hilux BEV in April, but the truck isn't sold in the U.S.—and Toyota isn't signaling that will change.Alphabet-owned Wing is dramatically expanding its on-demand drone partnership with Walmart, signaling that flying groceries and meds are becoming a real part of everyday commerce.Wing will expand drone delivery to 150 more Walmart stores, building on pilots in Dallas-Fort Worth and Atlanta.Wing's top 25% of customers order three times per week, mostly groceries like eggs, ground beef, produce, and snacks.Once complete, Wing will operate from 270+ Walmart locations, reaching roughly 10% of the U.S. population.Walmart remains Wing's primary commercial partner, even as the company continues testing larger drones capable of carrying five-pound payloads.Wing's new chief business officer Heather Rivera: “Volume is definitely powering our flywheel.”Join Paul J Daly and Kyle Mountsier every morning for the Automotive State of the Union podcast as they connect the dots across car dealerships, retail trends, emerging tech like AI, and cultural shifts—bringing clarity, speed, and people-first insight to automotive leaders navigating a rapidly changing industry.Get the Daily Push Back email at https://www.asotu.com/ JOIN the conversation on LinkedIn at: https://www.linkedin.com/company/asotu/

Can virtue defeat gods? SG-1's hunt for the Sangraal pits faith against force, while Ba'al and Adria turn allies into liabilities. Lisa Jones, Jeff Haecker, and Victor Lams weigh the cost of power—and Daniel's fate. The post The Quest (SG1) appeared first on StarQuest Media.

Steiny & Guru wonder what the fans will be feeling on Monday in the event of a loss, tight game, win... What is the headline when you wake up next time for S&G?

Tales of Three Campaign OneArc 2.1: OladellEpisode 67: Tuning Fork to the CityIt's party time! After all their hard work, our trio gets to relax, have one too many drinks, and play some games! Ivy and Rayla get closer, Novick has a heart to heart with Elara, and Véres makes plans to meet up with Jerek for a night cap.Content Warnings: Complicated Relationships, Profanity, Dating, Romance and Sexual SituationsTales of Three is an all-queer, dark fantasy dnd podcast where your three Game Masters are also your three Players!If you like what you hear please tell your friends about us & consider giving us a 5 star review! It's a quick and easy way to show your support for small creators whose content you enjoy!Follow the Cast:Arianna as Elara SpinelsparkDusty as Ivy Nightbreeze-TinkerfeyWayra as VéresFind our socials here!Want to chat with the cast, talk spoilers, play games, and make new friends? Join our Discord!If you want to help keep the podcast running and get access to bonus content check out our Patreon or buy us a coffee on Ko-fi!Special thanks to SG for theme song, Chriss for the logo, Fenn & Ely for the character art!Background music and SFX by Epidemic Sounds & Monument Studios.This week we're featuring our friends at Somebody's Heroes Podcast. Check out their podcast here!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

Hey YC Online! Sermon notes: https://static1.squarespace.com/static/592f36b4d1758e4fdf70080e/t/694b0623d07063222f1b331b/1766524451285/SG+01_4_26+KING+OF+HEARTS+Week+16.pdf ABOUT YOSEMITE CHURCH: Our mission is meeting people where they are and loving them to where Christ wants them to be. Yosemite Church wants to help you find your next step. Find locations, videos, and more info about us at https://yc.church/ or download the Yosemite Church app. NEXT STEPS: Have you made a decision to follow Jesus? You may be wondering what's next on your journey. We want to help! Let us guide you to your next steps in your walk with Christ: https://yc.church/baptism GIVE ONLINE: https://pushpay.com/g/yosemitechurch FIND US ON SOCIAL MEDIA: https://www.facebook.com/yosemitechurch https://www.instagram.com/yosemitechurch/ All music performed under MultiTrack License: 242540

Hey YC Online! Sermon notes: https://static1.squarespace.com/static/592f36b4d1758e4fdf70080e/t/69498a877768d12299baaf19/1766427271650/SG+12_28_25+Don%27t+chase+another+New+Year+%281%29.pdf ABOUT YOSEMITE CHURCH: Our mission is meeting people where they are and loving them to where Christ wants them to be. Yosemite Church wants to help you find your next step. Find locations, videos, and more info about us at https://yc.church/ or download the Yosemite Church app. NEXT STEPS: Have you made a decision to follow Jesus? You may be wondering what's next on your journey. We want to help! Let us guide you to your next steps in your walk with Christ: https://yc.church/baptism GIVE ONLINE: https://pushpay.com/g/yosemitechurch FIND US ON SOCIAL MEDIA: https://www.facebook.com/yosemitechurch https://www.instagram.com/yosemitechurch/ All music performed under MultiTracks Licenses: 242540

Tales of Three Campaign OneArc 2.1: Oladell Episode 67: Tuning Fork to the CityAfter their success of fixing the dam, TUO is honored by the town with a ceremony, given gifts, and has a celebration thrown in their name! Content Warnings: Anxiety, Emotional Distress, Profanity, and Romantic and Sexual Situations Tales of Three is an all-queer, dark fantasy dnd podcast where your three Game Masters are also your three Players!If you like what you hear please tell your friends about us & consider giving us a 5 star review! It's a quick and easy way to show your support for small creators whose content you enjoy! Follow the Cast:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Arianna⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠as Elara Spinelspark⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dusty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ as Ivy Nightbreeze- Tinkerfey  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Wayra⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ as Véres Find our socials ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!  Want to chat with the cast, talk spoilers, play games, and make new friends? Join our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Discord⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!  If you want to help keep the podcast running and get access to bonus content check out our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!Buy us a coffee on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ko-fi⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠! Special thanks to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SG ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for the theme music, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chriss ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for the logo, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fenn ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠& ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ely ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for the character art! Background music and SFX by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Epidemic Sounds⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠& ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Monument Studios⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠This week we're featuring our friends at Somebody's Heroes Podcast. Check out their podcast here!

Winter Total Request Live 2026 begins as Tread Perilously watches an episode of Stargate SG-1 called "Thor's Chariot." When the SG-1 team receives a distress signal from Cimmeria, they return to the planet finding a Goa'uld invasion and few Cimmerians left to fight. While O'Neil and Teal'c scout out the enemy encampment, Daniel and Sam learn the secret of Thor's might. Will it be enough to defeat the Goa'uld known as Heru'ur? Will anyone be able to pronounce their new adversary's name? And will Thor prove to be as real as Ra or his son? Erik and Justin discuss their histories with Stargate and SG-1. Erik makes a surprising proclamation about the work of director Roland Emmerich. Stan Lee proves to be more formidable than any Gou'ald. Pronunciations of Stargate names come into question, as does the choice to name the planet "Cimmeria". The SG-1 cast -- which includes Michael Shanks, Amanda Tapping, Christopher Judge, and Don S. Davis -- gets their flowers even if Erik has a small problem with Richard Dean Anderson playing Col. Jack O'Neil. Erik doubts Beth Grant's dedication to Sparkle Motion. The Ancient Astronaut Theory proves to be an obstacle in enjoying any Stargate. The pair once again advocate for cheaper-looking sci-fi television and Erik announces a change to the Patreon.

What happens when SG-1 wins through deception instead of firepower? Jeff Haecker, Lisa Jones, and Victor Lams break down a space-bound thriller full of cons, double-crosses, and Vala's street smarts—plus why “Company of Thieves” quietly highlights the team's versatility. The post Company of Thieves (SG1) appeared first on StarQuest Media.

Shoot us a Text.Why Dealers Will Win, Frozen Waymos, Gen Z Loves Holiday ShoppingDescription:Episode #1225: Cars Commerce's Alex breaks down why the future isn't car vending machines, Waymo robotaxis freeze during a San Francisco power outage, and Gen Z embraces the holiday experiences.SPONSOR READ:There will always be that customer who calls at 11:47 PM asking if the blue Tahoe is still available.Before Mia? That call went poof. Lost to the universe. And that customer? Who knows?Mia answers that customer at 11:47 pm, instantly and cheerfully. She books the appointment, checks inventory, sends the details, and suddenly that late-night caller becomes taillights over the curbShe's handled over a million customer calls to date and created millions in incremental revenue.Don't leave your late night callers hanging, give Mia a call. AnnouncementNext weeks 2026 Strategy Sessions12/26 Brian Benstock12/29 12/30 Brian Kramer12/31 Steve Greenfield1/1 2025 In Review1/2 Damon LesterUpcoming ASOTU Edge Webinar on January 7th at 2PM - AI That Works as Hard as You Do: Practical Tips for Faster Sales with Danny Veliz and Sarah HicksInterview with Cars Commerce CEO Alex Vetter - Show Notes with links:In a reflective interview, Cars Commerce leader Alex encourages dealers to use better tech to get leaner, faster, and more customer-friendly. Alex says the next wave of dealership tech has to reduce SG&A and improve operational efficiency, not just add more dashboards.He calls out a stubborn reality: sales per salesperson hasn't improved in about a decade, even as tools multiplied — and says AI should finally change that.He pushes back on the “dealers hate change” narrative, arguing dealers are highly adaptable entrepreneurs who will adopt what actually helps them win.The consumer journey gets more complicated closer to purchase, with more indecision around vehicle feel, color, space, and drive — meaning the funnel “widens” at the end.His bottom line: the winning model is omnichannel that finishes with a strong local dealer, saying, “I don't think the consumer wants a vending machine… they want an online experience that finishes with a local partner.”Waymo's driverless ride service ran into a very human problem this weekend: no power. A widespread outage across San Francisco left robotaxis frozen mid-ride, snarling traffic and raising fresh questions about how autonomous vehicles handle chaotic, real-world conditions.A power outage knocked out traffic lights across San Francisco, with social media videos showing mJoin Paul J Daly and Kyle Mountsier every morning for the Automotive State of the Union podcast as they connect the dots across car dealerships, retail trends, emerging tech like AI, and cultural shifts—bringing clarity, speed, and people-first insight to automotive leaders navigating a rapidly changing industry.Get the Daily Push Back email at https://www.asotu.com/ JOIN the conversation on LinkedIn at: https://www.linkedin.com/company/asotu/